[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 295
1. Kim YS, Shin DH, Choi JS, Kim KH: The Immunohistochemical Patterns of the beta-Catenin Expression in Pilomatricoma. Ann Dermatol; 2010 Aug;22(3):284-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pilomatricoma is a benign follicular tumor that is composed of basaloid cells, transitional cells and shadow cells. beta-Catenin is a 92-kDa protein, and it plays important roles in cell-cell adhesion at the cell membrane and signal transduction in the nucleus. beta-Catenin has recently been shown to play an important role in the formation of hair follicle-related tumors, including pilomatricoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):399-404 [10662767.001]
  • [Cites] Bioessays. 2000 Nov;22(11):961-5 [11056471.001]
  • [Cites] J Dermatol Sci. 2006 Jan;41(1):67-75 [16378715.001]
  • [Cites] Arch Dermatol. 1961 Apr;83:606-18 [13700704.001]
  • [Cites] Bull Cancer. 1999 Sep;86(9):725-6 [10519964.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):491-7 [10441606.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):410-3 [10192393.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] J Invest Dermatol. 1966 Apr;46(4):391-408 [5936043.001]
  • [Cites] Br J Dermatol. 2004 Mar;150(3):511-6 [15030335.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):732-6 [14608900.001]
  • [Cites] Br J Dermatol. 2001 Oct;145(4):624-9 [11703290.001]
  • [Cites] Br J Dermatol. 2001 Oct;145(4):576-81 [11703283.001]
  • [Cites] Cell. 2001 May 4;105(3):391-402 [11348595.001]
  • [Cites] J Cutan Pathol. 2007 Jun;34(6):467-73 [17518774.001]
  • (PMID = 20711264.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2917681
  • [Keywords] NOTNLM ; Immunohistochemical stain / Pilomatricoma / β-Catenin
  •  go-up   go-down


2. Bezdekova M, Brychtova S, Sedlakova E, Steigerova J, Hlobilkova A, Bienova M, Kucerova R, Brychta T, Krejci V, Kolar Z: Immunohistochemical assessment of E-cadherin and beta-catenin in trichofolliculomas and trichoepitheliomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Dec;151(2):251-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Trichofolliculomas and trichoepitheliomas are benign skin neoplasms originating from hair follicle cells.
  • They result from defects in the signaling pathways that regulate hair follicle morphogenesis and regeneration.
  • AIM: The aim of the present study was to investigate their involvement in benign hair follicle tumor development.
  • RESULTS: The intensity of E-cadherin/beta-catenin expression in tumor cells did not differ from controls.
  • However, normal hair follicles cells exhibited membranous E-cadherin/beta-catenin expression, whereas both types of tumors, particularly trichoepitheliomas, showed E-cadherin/beta-catenin expression with a predominantly cytoplasmic localization.
  • CONCLUSIONS: We suggest that this dystopic distribution of the E-cadherin/beta-catenin complex in hair follicle tumor cells may be a marker of cell-cell adhesion disruption which may contribute to the tumor formation.
  • [MeSH-major] Cadherins / analysis. Hair Diseases / metabolism. Neoplasms, Basal Cell / chemistry. Skin Neoplasms / chemistry. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18345259.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


3. Vera Sempere FJ, Artes Martínez MJ, Vera Sirera B, Bonet Marco J: Follicular adenomatoid odontogenic tumor: immunohistochemical study. Med Oral Patol Oral Cir Bucal; 2006 Jul;11(4):E305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular adenomatoid odontogenic tumor: immunohistochemical study.
  • Adenomatoid odontogenic tumor (AOT) is an uncommon benign odontogenic lesion that affects young patients, with female predominance, mainly in second decade, showing a radiolucent unilocular image associated with an unerupted tooth, usually a canine.
  • In spite of previous and confusing denominations, such as adenoameloblastoma or adenomatoid ameloblastic tumor, AOT is a benign tumor with a very low rate of recurrence, that show a peculiar morphological picture (basaloid appearance with glandular-like structures, calcifying areas, and amiloid-like material) that allow its histopathological recognition.
  • We present a clinicopathological analysis of a case of follicular AOT affecting the mandible in a 9 years-old female patient associated with unerupted lower left canine.
  • According to its benign character and low potential for recurrence, AOT revealed a scant proliferative activity (2-3% nuclei showed Ki-67 positivity) limited to some epithelial nodules (AE1-3 +) of fusiform appearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16816813.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Sata N, Kurogochi A, Endo K, Shimura K, Koizumi M, Nagai H: Follicular lymphoma of the pancreas: a case report and proposed new strategies for diagnosis and surgery of benign or low-grade malignant lesions of the head of the pancreas. JOP; 2007;8(1):44-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma of the pancreas: a case report and proposed new strategies for diagnosis and surgery of benign or low-grade malignant lesions of the head of the pancreas.
  • The present report describes a case of follicular lymphoma of the pancreas with unique CT and MRI findings.
  • CASE REPORT: A 58-year-old male complained of sudden abdominal pain, and routine ultrasonography detected an 8 cm hypoechoic tumor in the head of the pancreas.
  • The tumor was enucleated for diagnosis.
  • Follicular lymphoma is quite rare in the pancreas and gastrointestinal tract.
  • Enucleation is indicated for benign and low-grade malignant tumors of the pancreas, even if the tumor is located in the head of the pancreas.
  • [MeSH-major] Lymphoma, Follicular / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Benign Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228133.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Finn SP, Smyth P, Cahill S, Streck C, O'Regan EM, Flavin R, Sherlock J, Howells D, Henfrey R, Cullen M, Toner M, Timon C, O'Leary JJ, Sheils OM: Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. Virchows Arch; 2007 Mar;450(3):249-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy.
  • The most common sub-variant of papillary thyroid carcinoma (PTC) is the so-called follicular variant (FVPTC), which is a particularly problematic lesion and can be challenging from a diagnostic viewpoint even in resected lesions.
  • We used the recently developed Applied Biosystems 1700 microarray system to interrogate a series of 11 benign thyroid lesions and conditions and 14 samples of PTC (six with classic morphology and eight with follicular variant morphology).
  • Diminished expression of metallothioneins featured strongly among these and suggests a possible role for this family as tumour suppressors in PTC.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Papillary / genetics. Biomarkers, Tumor / genetics. Oligonucleotide Array Sequence Analysis / methods. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Winter;13(4):321-30 [12665650.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):735-44 [12640681.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):983-7 [14612978.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):844-56 [14871811.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2188-96 [14981541.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):1-6 [15145515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 [15356020.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Mol Endocrinol. 2004 Nov;18(11):2672-84 [15297606.001]
  • [Cites] Nature. 1987 Jul 9-15;328(6126):170-2 [3600795.001]
  • [Cites] Am J Pathol. 1987 Oct;129(1):177-82 [3661677.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] J Clin Invest. 1992 May;89(5):1517-22 [1569189.001]
  • [Cites] Virchows Arch. 1994;425(5):491-7 [7850073.001]
  • [Cites] Cancer Lett. 1995 Mar 2;89(2):195-200 [7889529.001]
  • [Cites] Histopathology. 1998 Apr;32(4):340-7 [9602331.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6B):4667-72 [9891538.001]
  • [Cites] J Pathol. 1999 May;188(1):87-92 [10398146.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):1-8 [15735849.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):1021-7 [15467430.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):59-73 [16051032.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Sep;90(9):5270-8 [15998773.001]
  • [Cites] Thyroid. 2005 Sep;15(9):977-87 [16187905.001]
  • [Cites] J Cell Biol. 2005 Nov 21;171(4):729-38 [16286510.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):805-11 [11351299.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 [10566678.001]
  • [Cites] Immunol Rev. 1999 Dec;172:109-20 [10631941.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):98-111 [10708852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1777-80 [12168868.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):938-41 [12574236.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • (PMID = 17252232.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.- / Taq Polymerase
  • [Other-IDs] NLM/ PMC1888716
  •  go-up   go-down


6. Ferreira RC, Ward LS, Adam RL, Leite NJ, Metze K, Matos PS: [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers]. Arq Bras Endocrinol Metabol; 2009 Oct;53(7):804-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers].
  • [Transliterated title] Contribuição da análise de textura do núcleo celular para o diagnóstico diferencial de lesões foliculares da tireoide: comparação com marcadores imunoistoquímicos.
  • OBJECTIVE AND METHODS: To investigate the utility of nuclear chromatin texture assessment in the differential diagnosis of follicular patterned lesions, by means of examining 76 samples previously submitted to the immunohistochemical protein analysis of HBME-1, CK-19 and galectina-3.
  • A series of morphometric, densitometric and texture variables were useful in the discrimination of the different types of follicular lesions.
  • Among these variables, r(2), a parameter related to the granularity of the nucleus presented the best accuracy, sensitivity, specificity and positive and negative predictive values, distinguishing benign from malignant lesions.
  • CONCLUSION: The morphometric analysis of nuclear chromatin images may add accuracy to the differential diagnosis of follicular patterned lesions.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / pathology. Cell Nucleus / pathology. Chromatin / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Bras Endocrinol Metabol. 2009 Oct;53(7):793-4 [19942979.001]
  • (PMID = 19942981.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


7. Saleh HA, Jin B, Barnwell J, Alzohaili O: Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol; 2010;5:9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
  • BACKGROUND: Thyroid nodules are common among adults though only a small percentage is malignant, which can histologically mimic benign nodules.
  • METHODS: We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52 hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22 follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC).
  • RESULTS: The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules.
  • The sensitivity of these markers for the distinction between benign and malignant lesions ranged from 83.3% to 87%.
  • Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions.
  • CONCLUSION: Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular. Carcinoma. Diagnosis, Differential. Galectin 3 / analysis. Humans. Hyperplasia. Keratin-19 / analysis. Predictive Value of Tests. Proto-Oncogene Proteins c-ret / analysis. Sensitivity and Specificity. Thyroid Neoplasms / chemistry. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Endocr Pathol. 2002 Fall;13(3):207-11 [12446919.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1117-23 [14614051.001]
  • [Cites] Acta Chir Iugosl. 2003;50(3):67-70 [15179758.001]
  • [Cites] J Endocrinol Invest. 2004 Apr;27(4):311-7 [15233548.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Head Neck. 2004 Nov;26(11):960-6 [15386597.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1175-81 [16251880.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):547-50 [16438854.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):28-34 [16514837.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jul;49(3):376-80 [17001889.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1631-7 [16998461.001]
  • [Cites] Ann Pathol. 2006 Oct;26(5):347-51 [17255922.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):213-23 [17308358.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):225-34 [17308359.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]
  • [Cites] Lancet Oncol. 2008 Jun;9(6):543-9 [18495537.001]
  • [Cites] Am J Clin Pathol. 2008 Nov;130(5):683-6 [18854259.001]
  • [Cites] Am J Clin Pathol. 2008 Nov;130(5):736-44 [18854266.001]
  • [Cites] Lancet. 2000 Dec 9;356(9246):2010-1 [11130546.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Diagn Cytopathol. 2002 Jun;26(6):366-72 [12112826.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • (PMID = 20181018.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; Thyroid cancer, Hurthle cell; Thyroid cancer, papillary
  • [Other-IDs] NLM/ PMC2831001
  • [General-notes] NLM/ Original DateCompleted: 20100524
  •  go-up   go-down


8. Shimanovich I, Krahl D, Rose C: Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol; 2010 Feb;62(2):277-83
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors.
  • BACKGROUND: Trichoadenoma is a rare benign follicular tumor first described by Nikolowski 50 years ago.
  • In trichoadenoma the cystic component predominates, while desmoplastic trichoepithelioma is a mostly solid neoplasm.
  • Trichoadenoma is a distinct follicular tumor related but not identical to desmoplastic trichoepithelioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratin-20 / metabolism. Male. Merkel Cells / pathology. Middle Aged. Neoplasms, Fibroepithelial / pathology. Receptors, Androgen / metabolism. Skin / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115950.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Receptors, Androgen; 0 / human epithelial antigen-125
  •  go-up   go-down


9. Fukushima M, Ito Y, Hirokawa M, Miya A, Kobayashi K, Akasu H, Shimizu K, Miyauchi A: Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule. World J Surg; 2009 May;33(5):963-8
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule.
  • However, in our experience, some MTC may be diagnosed as a follicular tumor or a benign nodule on ultrasonography because ultrasonographic findings of malignancy are lacking.
  • Of these patients, 54 were diagnosed as having thyroid carcinoma (malignant, or M-type) but the remaining 23 were diagnosed as having follicular tumor or benign nodule (benign, or B-type) on ultrasonography.
  • RESULTS: Clinically apparent lateral node metastasis, extrathyroid extension, and extranodal tumor extension were observed in 37%, 17%, and 11% of M-type patients, respectively, but none of the B-type patients showed any of these features.
  • Lymph node metastasis was pathologically confirmed in 38 and 65% of B-type and M-type patients, respectively.
  • However, thyroidectomy and lymph node dissection for B-type MTC should be the same as for M-type MTC because 38% of B-type MTC showed pathologic node metastasis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnostic imaging. Carcinoma, Medullary / diagnostic imaging. Thyroid Neoplasms / diagnostic imaging
  • [MeSH-minor] Adult. Aged. Calcitonin / blood. Carcinoembryonic Antigen / blood. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Analysis. Thyroidectomy. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Apr 15;77(8):1556-65 [8608543.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):415-9 [15837050.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):85-93 [17609406.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Clin Investig. 1993 Jan;71(1):7-12 [8095831.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Medicine (Baltimore). 1984 Nov;63(6):319-42 [6503683.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1305-11 [15517484.001]
  • [Cites] Am J Clin Pathol. 1978 Oct;70(4):587-94 [360824.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):808-14 [1643612.001]
  • [Cites] Laryngoscope. 2005 Aug;115(8):1445-50 [16094121.001]
  • [Cites] Thyroid. 2007 Dec;17 (12 ):1269-76 [17988196.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):815-21 [17968174.001]
  • [Cites] Mayo Clin Proc. 1992 Oct;67(10):934-40 [1434853.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1139-48 [10699905.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):806-16 [2448025.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83 [7906417.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):56-60 [15999359.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8 [10363903.001]
  • [Cites] Diagn Cytopathol. 2000 Jun;22(6):351-8 [10820528.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):132-8 [8988737.001]
  • [Cites] World J Surg. 2006 Jan;30(1):84-90 [16369705.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] World J Surg. 2009 Jan;33(1):58-66 [19005720.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] Endocr J. 2004 Oct;51(5):453-6 [15516777.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • (PMID = 19198929.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9007-12-9 / Calcitonin
  •  go-up   go-down


10. Bornstein MM, Filippi A, Altermatt HJ, Lambrecht JT, Buser D: [The odontogenic keratocyst--odontogenic cyst or benign tumor?]. Schweiz Monatsschr Zahnmed; 2005;115(2):110-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The odontogenic keratocyst--odontogenic cyst or benign tumor?].
  • [Transliterated title] Die odontogene Keratozyste--odontogene Zyste oder benigner Tumor?
  • The odontogenic keratocyst is the third most common cyst of the jaws, after the follicular and radicular cyst.
  • This led to the tentative suggestion that the keratocyst might be a benign cystic neoplasm rather than simply an odontogenic cyst.

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771334.001).
  • [ISSN] 0256-2855
  • [Journal-full-title] Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia
  • [ISO-abbreviation] Schweiz Monatsschr Zahnmed
  • [Language] FRE; GER
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 69
  •  go-up   go-down


11. Battistella M, Peltre B, Cribier B: Composite tumors associating trichoblastoma and benign epidermal/follicular neoplasm: another proof of the follicular nature of inverted follicular keratosis. J Cutan Pathol; 2010 Oct;37(10):1057-63
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite tumors associating trichoblastoma and benign epidermal/follicular neoplasm: another proof of the follicular nature of inverted follicular keratosis.
  • BACKGROUND: Trichoblastomas (TBs) are benign follicular tumors that can present either as solitary nodule or as multiple facial papules.
  • Only one case of sporadic TB in a composite tumor has been reported, arising in an apocrine poroma.
  • We report the association of TB and benign epidermal/follicular neoplasm in six patients.
  • The lesions associated with TB were inverted follicular keratosis (IFK) in three cases, seborrhoeic keratosis (SK) in two cases and IFK with verruca vulgaris pattern in one case.
  • It was often positive in the associated neoplasm.
  • CONCLUSION: TB can be associated with benign epidermal/follicular neoplasm in composite tumors.
  • The association of TB and IFK with direct connection between the lesions is another argument in favor of the follicular origin of IFK.
  • Composite tumors associating trichoblastoma and benign epidermal/follicular neoplasm: another proof of the follicular nature of inverted follicular keratosis.
  • [MeSH-minor] Adult. Aged. Female. Hair Diseases. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615018.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


12. Bayod MJ, Carlón ME, Idoate MA: [Pseudomeigs syndrome in a patient with Krukenberg's tumor]. Rev Med Univ Navarra; 2007 Jul-Sep;51(3):19-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomeigs syndrome in a patient with Krukenberg's tumor].
  • [Transliterated title] Síndrome de Pseudomeigs en paciente con tumor de Krukenberg.
  • The anatomopathological analysis showed bilateral ovarian implants from signet ring cell adenocarcinoma (Krukenberg tumor).
  • This patient developed a PseudoMeigs syndrome consisting on malignant ovarian tumor asociated with ascitis and pleural effusion without malignant cells.
  • Oncological patients who present with ascitis and benign pleural effusion, the diagnosis of PseudoMeigs syndrome should be considered.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Krukenberg Tumor / diagnosis. Meigs Syndrome / diagnosis. Neoplasms, Multiple Primary. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Ascites / etiology. Diagnosis, Differential. Diagnostic Imaging. Female. Fibroma / diagnosis. Humans. Lymphoma, Follicular. Middle Aged. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18183782.001).
  • [ISSN] 0556-6177
  • [Journal-full-title] Revista de medicina de la Universidad de Navarra
  • [ISO-abbreviation] Rev Med Univ Navarra
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


13. Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Höög A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A: Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol; 2006;27(4):211-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
  • OBJECTIVE: To identify molecular markers useful for the diagnostic discrimination of benign and malignant follicular thyroid tumors.
  • A robust algorithm for gene selection was developed to identify molecular markers useful for the classification of heterogeneous tumor classes.
  • The study included tumor tissue specimens from 10 patients with benign follicular adenomas and from 10 with malignant tumors.
  • The malignant tumors mainly consisted of clinically relevant minimally invasive follicular carcinomas.
  • The results indicate that a small number of genes can be useful to distinguish follicular adenomas from follicular carcinomas.
  • These genes have the potential for molecular classification of follicular thyroid tumors and for providing improved understanding of the molecular mechanisms involved in thyroid malignancies.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adult. Aged. DNA Primers. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16675914.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers
  •  go-up   go-down


14. Freitas BC, Cerutti JM: Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol Cell Endocrinol; 2010 May 28;321(1):77-85
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
  • The main problem established by a discovery of a thyroid nodule is to discriminate between a benign and malignant lesion.
  • While the overall accuracy of FNA for classical papillary thyroid carcinoma (PTC) approaches 100%, it has limited accuracy with follicular lesions.
  • Patients with a cytological report of indeterminate or follicular lesions are referred to surgery for a more accurate diagnosis.
  • Several studies have looked into biologic markers that could be used as an adjuvant to distinguish the benign from malignant nodules.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics. Thyroid Nodule / diagnosis. Thyroid Nodule / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19932149.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 140
  •  go-up   go-down


15. Hamsch C, Hartschuh W: Microcystic adnexal carcinoma - aggressive infiltrative tumor often with innocent clinical appearance. J Dtsch Dermatol Ges; 2010 Apr;8(4):275-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma - aggressive infiltrative tumor often with innocent clinical appearance.
  • Histologic characteristics are follicular and glandular differentiation, as well as bland cytologic features.
  • The benign histologic appearance, particularly in the upper level of the tumor, can be confused with syringoma or benign follicular neoplasm.
  • We report two patients with microcystic adnexal carcinoma, using them as a basis to discuss, pathogenesis, diagnosis, histology and therapy of the tumor.

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788582.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Weyers W, Hörster S, Diaz-Cascajo C: Tumor of follicular infundibulum is Basal cell carcinoma. Am J Dermatopathol; 2009 Oct;31(7):634-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor of follicular infundibulum is Basal cell carcinoma.
  • Tumor of follicular infundibulum (TFI) is currently thought to be a benign epithelial neoplasm with follicular differentiation.
  • We reexamined 24 cases of TFI and noted, often only focally, many changes typical of BCC, including palisading of cells at the periphery of aggregations, germinative cells, follicular germs in the absence of a follicular papilla, crowding of cells, individual necrotic neoplastic cells, fibromucinous stroma, and clefts between aggregations of neoplastic cells and stroma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652582.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rongioletti F, De Lucchi S, Meyes D, Mora M, Rebora A, Zupo S, Cerruti G, Patterson JW: Follicular mucinosis: a clinicopathologic, histochemical, immunohistochemical and molecular study comparing the primary benign form and the mycosis fungoides-associated follicular mucinosis. J Cutan Pathol; 2010 Jan;37(1):15-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular mucinosis: a clinicopathologic, histochemical, immunohistochemical and molecular study comparing the primary benign form and the mycosis fungoides-associated follicular mucinosis.
  • OBJECTIVES: To determine (i) whether primary (idiopathic) follicular mucinosis (PFM) and lymphoma-associated follicular mucinosis (LAFM) are distinct or related entities and whether there are reliable criteria that allow the two forms to be distinguished, (ii) the histochemical properties and consequently the type of mucin that accumulates in the follicle in PFM and LAFM, and (iii) whether there is any difference between the staining properties of mucin in patients with PFM and LAFM.
  • No differences were found in the composition of the follicular mucin in the PFM compared with LAFM.
  • [MeSH-major] Mucinosis, Follicular / pathology. Mycosis Fungoides / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Gene Rearrangement. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mucins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19615011.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


18. Paramo JC, Mesko T: Age, tumor size, and in-office ultrasonography are predictive parameters of malignancy in follicular neoplasms of the thyroid. Endocr Pract; 2008 May-Jun;14(4):447-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, tumor size, and in-office ultrasonography are predictive parameters of malignancy in follicular neoplasms of the thyroid.
  • OBJECTIVE: To identify clinical predictors of malignancy in patients with intraoperative frozen-section diagnosis of follicular neoplasm of the thyroid.
  • METHODS: We performed a retrospective cross-sectional study of 71 patients with intraoperative frozen-section diagnosis of follicular neoplasm who underwent thyroidectomy between January 1992 and December 2000.
  • Age, sex, tumor size, and in-office ultrasonography characteristics of the lesions were assessed.
  • These clinical factors were compared between cases that had benign definitive pathologic findings and those that were found to be carcinomas on permanent sections.
  • RESULTS: Nine (13%) of the 71 follicular neoplasms were found to be carcinomas after definitive pathologic evaluation.
  • When the in-office ultrasonography findings were interpreted as benign, only 7% (3/46) of cases were malignant compared with 40% (4/10) when the ultrasonography findings were suspicious (P = .02).
  • CONCLUSIONS: Age and tumor size are predictive parameters of malignancy in follicular neoplasm of the thyroid.
  • Total thyroidectomy is reasonable in patients with follicular neoplasm on frozen section if they are young (<45 years old), with large (>4 cm) tumors or if there are suspicious findings on in-office ultrasonography.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / pathology. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Age Factors. Cross-Sectional Studies. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558598.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, Waite KA, Eng C: Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab; 2005 Feb;90(2):1149-55
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis.
  • The two most common subtypes of thyroid cancer, follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma, have been extensively studied, but our fundamental understanding of the molecular events in thyroid epithelial oncogenesis is still limited.
  • Unreported data from our previous published global gene expression analysis revealed that the tumor suppressor gene aplysia ras homolog I (ARHI) is frequently underexpressed in FTCs.
  • In this study, we elucidated the frequency and mechanism of ARHI silencing in benign and malignant thyroid neoplasia.
  • We demonstrated that underexpression of ARHI occurs principally in FTCs (P = 0.0018), including its oncocytic variant (11 of 13), even at minimally invasive stage but not classic papillary thyroid carcinoma (two of seven) or follicular adenoma (FA) (three of 14).
  • Therefore, our data suggest that silencing of the putative maternally imprinted tumor suppressor gene ARHI, primarily by large genomic deletion in conjunction with hypermethylation of the genomically imprinted allele, serves as a key early event in follicular thyroid carcinogenesis.
  • [MeSH-major] Azacitidine / analogs & derivatives. Gene Silencing. Genes, Tumor Suppressor. Genomic Imprinting / genetics. Thyroid Neoplasms / genetics. rho GTP-Binding Proteins / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / pathology. Antimetabolites, Antineoplastic / pharmacology. Base Sequence. DNA Primers. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Loss of Heterozygosity. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15546898.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16059
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DIRAS3 protein, human; 0 / DNA Primers; 776B62CQ27 / decitabine; EC 3.6.5.2 / rho GTP-Binding Proteins; M801H13NRU / Azacitidine
  •  go-up   go-down


20. Kołomecki K, Maciaszczyk P, Stepień H, Cywiński J, Cielecka J, Stepień T, Kuzdak K: [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors]. Endokrynol Pol; 2006 Jul-Aug;57(4):320-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors].
  • The aim of study was evaluation of p53 and sFasL blood concentration in patients with benign follicular adenoma and follicular thyroid cancer.
  • MATERIALS AND METHODS: The study population was composed of 28 patients: 14 with thyroid carcinoma and 14 patients with follicular neoplasm (NF).
  • RESULTS: The analysis revealed high sFasL blood concentration in patients with follicular thyroid cancer in comparison with the group with follicular adenoma.
  • CONCLUSIONS: Evaluation of sFasL serum level concentration may be useful in preoperative diagnosis of follicular thyroid tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenoma / blood. Biomarkers, Tumor / blood. Fas Ligand Protein / blood. Thyroid Neoplasms / blood. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Apoptosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006831.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fas Ligand Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


21. Besic N, Sesek M, Peric B, Zgajnar J, Hocevar M: Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit; 2008 Sep;14(9):CR459-67
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid.
  • BACKGROUND: The aim of this retrospective study was to find predictive factors of carcinoma in patients with follicular neoplasm.
  • The specific aim was to discover whether preoperative serum thyroglobulin (Tg) concentration in patients with thyroid neoplasm can differentiate between those with thyroid carcinoma and those with benign disease.
  • MATERIAL/METHODS: A total of 327 patients (263 females, 64 males, median age: 51.5 years) with follicular neoplasm in whom carcinoma was only suspected and who were surgically treated at the authors' institute in 1988-2004 were included in the study.
  • RESULTS: The histopathological diagnoses were carcinoma, benign goiter, and adenoma in 119 (36%), 104 (32%), and 104 (32%) patients, respectively.
  • The independent predictors of malignancy as shown by multivariate logistic regression were tumor diameter and preoperative Tg concentration.
  • Thyroid carcinoma was more common in the patients with follicular neoplasm and serum Tg concentration over 300 ng/ml than in those with lower Tg concentrations.
  • CONCLUSIONS: Predictors of malignancy were tumor diameter and preoperative Tg concentration.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758416.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


22. Socolovsky M, Spaho N, Cueto DG, Doglietto F, Fernandez E: Reactive lymphoid follicular hyperplasia mimicking a peripheral nerve tumor. Surg Neurol; 2008 Nov;70(5):514-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive lymphoid follicular hyperplasia mimicking a peripheral nerve tumor.
  • BACKGROUND: Reactive lymphoid follicular hyperplasia is a benign proliferation of lymphoid follicles, which can develop wherever lymphoid tissue is present.
  • We present the unique case of an RLFH that involved the radial nerve and presented as a peripheral nerve tumor.
  • Magnetic resonance findings revealed a contrast-enhancing, spindle-shaped tumor, suggestive of a schwannoma or neurofibroma, along the course of the radial nerve.
  • The intraoperative appearance was that of an infiltrating tissue around a lateral branch of the nerve, which could be resected en bloc.
  • Pathologic examination documented hyperplastic lymphoid tissue surrounding the nerve, and immunostaining confirmed the diagnosis of benign reactive follicular hyperplasia.
  • CONCLUSION: To our knowledge this is the first description of RLFH affecting a peripheral nerve and mimicking a neoplasm.
  • This rare and benign condition should be considered in the differential diagnosis of peripheral nerve tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18261777.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M: The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Exp Oncol; 2006 Mar;28(1):70-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
  • We have evaluated immunohistochemical assay of TPO for distinguishing follicular thyroid carcinoma from follicular adenoma.
  • MATERIALS AND METHODS: Sections of formalin-fixed tissues obtained from 92 patients with thyroid tumors (52 follicular carcinomas and 40 follicular adenomas including the Hurthle cell type) were analyzed using a monoclonal antibody (TPO mAb 47) and the avidin-biotin peroxidase complex immunohistochemical technique.
  • Lesions with staining of more than 80% of the follicular cells/specimen were considered benign, while less than 80% were considered malignant.
  • RESULTS: TPO immunostaining correlated with the histopathological diagnosis in 24/40 cases of follicular adenomas and 41/52 cases of follicular carcinomas, giving a specificity of 60% and a sensitivity of 79%.
  • CONCLUSION: These results suggest that immunohistochemical assay of TPO expression has limited value for the differential diagnosis of follicular thyroid carcinoma from thyroid follicular adenoma.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614712.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


24. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J: Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer; 2008 Jan;47(1):56-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
  • The identification of molecular markers allowing to differentiate between benign and malignant thyroid tumors remains a diagnostic challenge.
  • RNA from 64 formalin-fixed paraffin-embedded thyroid tissues including normal tissue (n = 3), thyroiditis (n = 2), and follicular adenomas (n = 19) as well as follicular (n = 9), papillary (n = 28), and anaplastic (n = 3) carcinomas was reverse transcribed.
  • Expression differences of up to 400-fold were detected between benign and malignant thyroid tumors.
  • Based on HMGA2 expression alone, it was possible to distinguish between benign and malignant thyroid tissues with a sensitivity of 95.9% and a specificity of 93.9%.
  • There was a highly significant (P < 0.001) difference with histology of the tumors being the gold standard between the benign lesions and malignant tumors.
  • Our results show that even as a stand-alone marker HMGA2 expression has a high potential to improve diagnoses of follicular neoplasms of the thyroid.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Biomarkers, Tumor / genetics. HMGA2 Protein / genetics. Thyroid Neoplasms / genetics. Up-Regulation / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943974.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / HMGA2 Protein
  •  go-up   go-down


25. Kameyama K, Ito K, Takami H: [Pathology of benign thyroid tumor]. Nihon Rinsho; 2007 Nov;65(11):1973-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathology of benign thyroid tumor].
  • True benign neoplasm of the thyroid gland is only follicular adenoma, which is a tumor derived from follicular cells.
  • Follicular adenoma is well-circumscribed, with no evidence of capsular or vascular invasion.
  • The architectural pattern of follicular adenoma varies from trabecular to macrofollicular, and in most instances more than one architectural pattern is observed in one tumor.
  • Adenomatous goiter, a hyperplastic lesion of follicles, is the most common tumorous lesion of thyroid gland.
  • The hyperplasia is followed by involution of the follicles leading to large follicles of varying size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018557.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 2
  •  go-up   go-down


26. Hunt JL, Yim JH, Carty SE: Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors. Thyroid; 2006 Jul;16(7):643-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractional allelic loss of tumor suppressor genes identifies malignancy and predicts clinical outcome in follicular thyroid tumors.
  • Thyroid follicular tumors can be challenging diagnostically and clinically, because the cytologic and histologic features can be subtle and prognosis is also difficult to predict.
  • In this study, we analyzed thyroid follicular tumors with known long-term follow-up for a molecular panel of tumor suppressor genes to determine whether this molecular approach has prognostic significance.
  • Microdissection and DNA extraction were performed from tumor and normal tissue.
  • Polymerase chain reaction (PCR) was performed for 13 short tandem repeats at or near tumor suppressor genes.
  • The mean FAL for benign tumors (14%) was significantly different from that of malignant tumors (56%, p < 0.001).
  • Patients with a follicular tumor who had no evidence of disease recurrence had a mean FAL of 22% and those with disease recurrence or death from disease had a mean of 78% (p < 0.002).
  • Based on these results, a tumor suppressor gene panel for allelic imbalance in follicular-derived tumors (FTT) may correlate with both malignancy and outcome in patients with follicular-derived carcinomas of the thyroid.
  • [MeSH-major] Adenoma / genetics. Adenoma / therapy. Carcinoma / genetics. Carcinoma / therapy. Genes, Tumor Suppressor. Loss of Heterozygosity. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889487.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 9007-49-2 / DNA
  •  go-up   go-down


27. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol; 2006;17(3):225-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.
  • BACKGROUND: Several immunohistochemical markers have been used to aid in the diagnosis of follicular-derived lesions of the thyroid (FDLT).
  • In this study we analyze the diagnostic efficacy of an immunopanel of antibodies to cytokeratin-19 (CK19), galectin-3 (GAL-3), HBME-1, anti-MAP kinase (ERK), ret-oncoprotein (RET), and p16 using a tissue microarray consisting of both benign and malignant FDLT.
  • DESIGN: The study cohort consisted of 90 cases of FDLT (53 benign, 37 malignant) embedded in a microarray and immunostained with antibodies to CK19, Gal-3, HMBE-1, ERK, RET, and p16.
  • RESULTS: HMBE-1 was expressed in 70% of malignant and 10% of benign FDLT (p value: <0.0001).
  • CK19 and GAL-3 were positive in 70% and 73% of malignant lesions, respectively, and 34% of benign FDLT (p value 0.0005 and 0.0015, respectively).
  • ERK was positive in 4% of the benign and 32% of the malignant cases (p value 0.0002).
  • p16 was expressed in 2% and 46% of the benign and malignant lesions, respectively (p value 0.0001).
  • RET positivity was identified in 15% of the benign lesions and 27% of the malignant cases (p value 0.0016).
  • CONCLUSIONS: HBME-1, ERK, and p16 were more specific for malignancy, whereas CK19 and GAL-3 stained benign lesions with a higher frequency and were not specific for malignant FDLT.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):165-6 [12162672.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):15-20 [11223556.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):216-22 [9930143.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1166-71 [10534163.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2185-93 [9827724.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1331-7 [1620547.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1373-6 [10571520.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):250-7 [14715858.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):307-11 [11038428.001]
  • [Cites] Pathol Res Pract. 2003;199(6):399-404 [12924440.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Rev Med Chil. 2004 Mar;132(3):279-84 [15376563.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):257-69 [16601293.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4294-302 [15240514.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4011-8 [15840741.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):603-5; author reply 605-6 [12375649.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Dec;32(6):530-3 [14761598.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Histopathology. 2004 Jul;45(1):39-46 [15228442.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Oncogene. 1994 Feb;9(2):509-16 [8290261.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):259 [7913169.001]
  • [Cites] Pol J Pathol. 2004;55(4):143-8 [15757201.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Eur J Endocrinol. 2002 Oct;147(4):515-21 [12370115.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):319-22 [14974863.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):70-4 [9894456.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5152-8 [11701669.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):311-6 [10478135.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):87-95 [15742329.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):1-8 [15735849.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):331-7 [8133143.001]
  • [Cites] Histopathology. 2001 Jul;39(1):25-32 [11454041.001]
  • (PMID = 17308359.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Galectin 3; 0 / HBME-1 antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


28. Ramos-Ceballos FI, Pashaei S, Kincannon JM, Morgan MB, Smoller BR: Bcl-2, CD34 and CD10 expression in basaloid follicular hamartoma, vellus hair hamartoma and neurofollicular hamartoma demonstrate full follicular differentiation. J Cutan Pathol; 2008 May;35(5):477-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2, CD34 and CD10 expression in basaloid follicular hamartoma, vellus hair hamartoma and neurofollicular hamartoma demonstrate full follicular differentiation.
  • Generalized basaloid follicular hamartoma syndrome (GBFHS) is a rare, recently-described, autosomal-dominantly inherited disorder that presents with disseminated milia, palmoplantar pitting, hypotrichosis and basaloid follicular hamartomas (BFH).
  • BFH is a benign adnexal tumor that resembles basal cell carcinoma (BCC).
  • In this study, we report two cases of GBFHS and stain BFH, a vellus hair hamartoma (VHH) and a neurofollicular hamartoma (NH) with CD34, bcl-2 and CD10 to characterize and compare the staining patterns of these follicular tumors.
  • These results show the similarities in differentiation between these benign follicular neoplasms and trichoepithelioma.
  • [MeSH-major] Antigens, CD34 / metabolism. Hair Diseases / metabolism. Hamartoma Syndrome, Multiple / metabolism. Neprilysin / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Biomarkers / metabolism. Child. Child, Preschool. Epidermal Cyst / metabolism. Epidermal Cyst / pathology. Female. Hair Follicle / metabolism. Hair Follicle / pathology. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Basaloid Follicular Hamartoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 May;36(5):603; author reply 604 [19476535.001]
  • (PMID = 18399809.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


29. Granados-García M, Cortés-Flores AO, del Carmen González-Ramírez I, Cano-Valdez AM, Flores-Hernández L, Aguilar-Ponce JL: Follicular neoplasms of the thyroid: importance of clinical and cytological correlation. Cir Cir; 2010 Nov-Dec;78(6):473-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular neoplasms of the thyroid: importance of clinical and cytological correlation.
  • Fine needle aspiration biopsy (FNAB) is useful for initial evaluation; nevertheless, malignancy is uncertain when follicular neoplasm is reported.
  • Therefore, we analyzed our follicular neoplasms in order to identify those factors associated with a higher risk of malignancy.
  • METHODS: We analyzed the clinical files of consecutive patients with cytological diagnoses of follicular neoplasm.
  • RESULTS: From 1,005 cases of thyroid nodules, 121 were follicular neoplasms according to cytology.
  • Definitive report showed 45 benign (60%) and 30 malignant (40%) cases.
  • Benign cases included 29 goiters, 11 follicular adenomas, and 5 cases of thyroiditis.
  • Malignant cases were comprised of 12 papillary carcinomas, 4 follicular carcinomas, 3 papillary carcinomas-follicular variant, 1 lymphoma, 1 teratoma, 5 medullary carcinomas, 2 insular carcinomas, 1 anaplastic carcinoma and 1 metastatic breast carcinoma.
  • Tumor size of benign lesions was 3.43 ± 2.04 cm, and 4.67 ± 2.78 (p = 0.049) for malignant lesions.
  • Age was 46.95 ± 15.39 years for benign lesions and 48.67 ± 17.28 for malignant lesions (p = 0.66).
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21214982.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


30. Costanzo M, Caruso LA, Messina DC, Cavallaro A, Palumbo A, Marziani A, Cannizzaro MA: [Thyroid microcarcinoma in benign thyroid diseases]. Ann Ital Chir; 2005 Mar-Apr;76(2):119-21; discussion 121-2
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyroid microcarcinoma in benign thyroid diseases].
  • [Transliterated title] Il microcarcinoma tiroideo nelle tireopatie benigne.
  • INTRODUCTION: Thyroid microcarcinoma is a malignant thyroid tumor with potential multifocality and a maximum of 1 cm of diameter.
  • AIM OF THE STUDY: To appraise the incidence of MCT in the benign thyroid diseases and the advantages offered from the total thyroidectomy, performed for benign diffused thyroid diseases, which surgical treatment "therapeutic" performed for these malignant tumors.
  • MATERIALS AND METHODS: The study was conducted on 600 patients operated with total thyroidectomy for benign thyroid disease, admitted from 1999 to 2003.
  • Therefore his discovery, almost always accidental on a thyroid removed for other pathology, it has signaled by histologic study CONCLUSIONS: Thyroid microcarcinoma is a slow growing tumor, with a good prognosis and with a good disease-free survival.
  • Therefore total thyroidectomy can be considered best treatment and also be surgical treatment oncologically correct for this tumor.
  • [MeSH-major] Carcinoma, Papillary / surgery. Carcinoma, Papillary, Follicular / surgery. Thyroid Diseases / surgery. Thyroid Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302649.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS: Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid; 2010 Sep;20(9):981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
  • BACKGROUND: The most common type of ovarian germ cell tumor is the teratoma.
  • Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma.
  • Here we review this topic and illustrate major features by presenting multimodal management of a patient with BRAF-positive disseminated follicular thyroid cancer arising in an ovarian teratoma.
  • SUMMARY: Malignant thyroid tissue is often difficult to distinguish from benign thyroid tissue arising in ovarian teratomas.
  • Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from malignant struma ovarii.
  • During her next pregnancy, pelvic masses were noted; biopsies revealed well-differentiated papillary thyroid carcinoma, follicular variant.
  • The tumor was found to be BRAF mutation positive (K601E).

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Jun 18;360(25):2680-1; author reply 2682-3 [19537322.001]
  • [Cites] Endocr Pract. 2009 Mar;15(2):167-73 [19289330.001]
  • [Cites] Histopathology. 2009 Oct;55(4):482-7 [19817905.001]
  • [Cites] Endocr Pathol. 2010 Jun;21(2):144-7 [19898969.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):225-6 [10785468.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3512-5 [11502772.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):575-7 [11520159.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] J Reprod Med. 2003 Jan;48(1):52-6 [12611097.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):226-8 [15262148.001]
  • [Cites] Clin Nucl Med. 1988 Dec;13(12):866-8 [3246114.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jul;69(1):186-90 [2499590.001]
  • [Cites] Int J Gynaecol Obstet. 1993 Aug;42(2):143-6 [7901063.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] Pathol Res Pract. 1994 Nov;190(11):1082-5; discussion 1086-8 [7746743.001]
  • [Cites] Histopathology. 1997 Sep;31(3):289-90 [9354902.001]
  • [Cites] J Postgrad Med. 1996 Apr-Jun;42(2):39-42 [9715297.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):912-6 [10084570.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):282-4 [15790478.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Jun;17(3):299-308 [15870565.001]
  • [Cites] Hum Pathol. 2005 Jun;36(6):694-7 [16021577.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1156-9 [16343201.001]
  • [Cites] Thyroid. 2005 Dec;15(12):1355-61 [16405408.001]
  • [Cites] Pathology. 2007 Feb;39(1):139-46 [17365830.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):321-4 [17240432.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):116-20 [17478764.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1337-43 [17721188.001]
  • [Cites] Endocr Pathol. 2007 Fall;18(3):182-6 [18058267.001]
  • [Cites] Clin Nucl Med. 2008 Apr;33(4):247-50 [18356660.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):213-22 [18317221.001]
  • [Cites] Gynecol Endocrinol. 2008 Jun;24(6):312-9 [18584410.001]
  • [Cites] Ultrasound Obstet Gynecol. 2008 Aug;32(2):210-9 [18636616.001]
  • [Cites] Ceylon Med J. 2008 Jun;53(2):55-6 [18678124.001]
  • [Cites] Int J Gynecol Pathol. 2008 Oct;27(4):496-506 [18753973.001]
  • [Cites] Obstet Gynecol Surv. 2008 Nov;63(11):725-32 [18928577.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Apr 1;190(1):15-20 [19264228.001]
  • [Cites] Thyroid. 2009 Oct;19(10):1093-8 [19732012.001]
  • (PMID = 20718682.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 9FN79X2M3F / Lithium; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; Q51BO43MG4 / Thyroxine
  • [Other-IDs] NLM/ PMC2964358
  •  go-up   go-down


32. Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F, Yasuoka H, Kakudo K, Inohara H, Kuma K, Miyauchi A: Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology; 2005 Aug;37(4):296-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.
  • AIMS: Galectin-3, a member of the beta-galactoside binding family of lectins, has been regarded as a useful tool for discriminating malignant tumours from benign nodules of the thyroid, including the distinction between follicular carcinoma and adenoma.
  • However, there are follicular tumours with unclear vascular or capsular invasion, which makes diagnosis more difficult.
  • In this study, we investigated the relationship between galectin-3 expression and the degree of vascular or capsular invasion of follicular tumours.
  • METHODS: We immunohistochemically investigated galectin-3 expression in 260 cases of follicular tumour with various degrees of vascular or capsular invasion classified into four categories.
  • However, its diagnostic value for follicular carcinoma was not high because the sensitivity and specificity were 68.7% and 57.5%, respectively.
  • CONCLUSIONS: Our findings suggest that galectin-3 plays a role in the transformation of follicular tumours from benign to malignant; however, when diagnosing follicular tumours, the presence of this protein should not be required for diagnosing malignant transformation in all cases.
  • Therefore, we must conclude that galectin-3 should only be considered an adjuvant marker for follicular carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Biomarkers, Tumor / analysis. Galectin 3 / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194828.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


33. Asa SL: The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol; 2005;16(4):295-309
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.
  • The differential diagnosis includes numerous entities, non-neoplastic and neoplastic, benign and malignant.
  • However, the diagnosis of follicular-patterned lesions remains an area fraught with controversy and diagnostic criteria are highly variable.
  • No single marker can identify all malignant follicular-patterned lesions, however, various combinations have been proposed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1996 Sep 5;13(5):1099-1102 [8806700.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):198-203 [9443391.001]
  • [Cites] Nature. 1987 Jul 9-15;328(6126):170-2 [3600795.001]
  • [Cites] Int J Surg Pathol. 2004 Apr;12(2):107-15 [15173915.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):375-88 [9445196.001]
  • [Cites] J Clin Invest. 1992 May;89(5):1517-22 [1569189.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):553-62 [1975986.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Am J Surg. 1993 Oct;166(4):331-5 [8214286.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] Endocr Rev. 1989 May;10(2):125-35 [2666115.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1814-8 [11932323.001]
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):424-31 [8293410.001]
  • [Cites] Eur J Endocrinol. 2004 Sep;151(3):367-74 [15362967.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):283-90 [2312106.001]
  • [Cites] Int J Mol Med. 2004 Oct;14(4):517-27 [15375577.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Am J Clin Pathol. 1992 Mar;97(3):426-34 [1543168.001]
  • [Cites] Recent Results Cancer Res. 1988;106:131-8 [3285408.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):631-5 [8503737.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2414-23 [9191532.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1331-7 [1620547.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):130-4 [9435429.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2946-53 [7559879.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Am J Med. 1994 Nov;97(5):418-28 [7977430.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1441-4 [1620555.001]
  • [Cites] In Vivo. 2004 Mar-Apr;18(2):189-95 [15113046.001]
  • [Cites] West J Med. 1996 Sep;165(3):131-8 [8909165.001]
  • [Cites] Tumori. 1993 Oct 31;79(5):314-20 [8116073.001]
  • [Cites] Thyroid. 1994 Summer;4(2):233-6 [7920009.001]
  • [Cites] World J Surg. 1988 Aug;12(4):488-95 [3048000.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4355-65 [15192042.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):846-51 [8370709.001]
  • [Cites] Pathol Annu. 1983;18 Pt 1:221-53 [6877876.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2144-7 [9187112.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):120-5 [1973172.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):809-17 [6660353.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):555-98 [9210356.001]
  • [Cites] Surg Gynecol Obstet. 1974 Oct;139(4):555-60 [4479589.001]
  • [Cites] Jpn J Surg. 1984 Mar;14(2):110-7 [6748382.001]
  • [Cites] Surgery. 1984 Dec;96(6):972-80 [6505970.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Am J Clin Pathol. 2003 Aug;120(2):175-81 [12931546.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):4116-22 [9814501.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):585-9 [8761374.001]
  • [Cites] Surgery. 1992 Dec;112(6):1130-6; discussion 1136-8 [1455315.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):463-8 [15483076.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):711-6; discussion 716-7 [1413840.001]
  • [Cites] Exp Oncol. 2004 Dec;26(4):282-6 [15627060.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Thyroid. 1996 Oct;6(5):409-16 [8936664.001]
  • [Cites] Arch Intern Med. 1996 Oct 28;156(19):2165-72 [8885814.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2695-701 [9253356.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1810-3 [11932322.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2187-90 [11344225.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):253-7 [11886339.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1093-7 [8806699.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):225-32 [14990587.001]
  • [Cites] J Clin Invest. 1985 Nov;76(5):1992-2002 [4056062.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Mod Pathol. 1996 Aug;9(8):816-20 [8871922.001]
  • [Cites] Diagn Mol Pathol. 1995 Jun;4(2):113-21 [7551291.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1306-7 [9100614.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 [15001635.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Feb;60(2):376-80 [3965495.001]
  • [Cites] Pathol Annu. 1985;20 Pt 1:1-44 [3887295.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Pathol Annu. 1994;29 ( Pt 2):99-120 [7936753.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6 [716909.001]
  • [Cites] Acta Pathol Jpn. 1986 Oct;36(10):1469-75 [3799186.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Oncogene. 1996 Apr 18;12 (8):1821-6 [8622903.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Sep;11(1):51-7 [7529046.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] Thyroid. 2004 Mar;14(3):169-75 [15072698.001]
  • [Cites] Endocr Rev. 1982 Winter;3(1):40-61 [6277609.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Endocr Pathol. 2004 Summer;15(2):107-16 [15299197.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):244-50 [7519046.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):635-6 [11710678.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3780-9 [15172984.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] Am J Surg Pathol. 1977 Jun;1(2):123-30 [602974.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3360-5 [8784097.001]
  • [Cites] Thyroid. 1997 Jun;7(3):337-42 [9226200.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20 [1542652.001]
  • [Cites] Am J Surg Pathol. 1992 Apr;16(4):392-400 [1373582.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1517-20 [2311063.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):183-8 [15252732.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Acta Pathol Jpn. 1985 Jul;35(4):781-8 [4072672.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1207-10 [7566982.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):237-40 [11886336.001]
  • [Cites] Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76 [2261906.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 [12970315.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):797-807 [6660352.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):331-7 [8133143.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):805-28 [3967175.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • (PMID = 16627917.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 129
  •  go-up   go-down


34. Kim MJ, Kim HJ, Hong SJ, Shong YK, Gong G: Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol; 2006 Jan-Feb;50(1):28-34
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
  • OBJECTIVE: To investigate the expression of galectin-3 in various thyroid follicular lesions, including diffuse hyperplasia, nodular hyperplasia, and benign and malignant follicular neoplasms, to clarify the diagnostic utility of galectin-3 in aspirates of follicular lesions.
  • STUDY DESIGN: A total of 146 follicular lesions diagnosed cytologically, obtained from patients who had undergone thyroidectomy for either benign or malignant nodules, were evaluated using Papanicolaou-stained slides and cell blocks with galectin-3 immunostaining.
  • We primarily categorized the aspirated specimens as benign, indeterminate or suspicious for a follicular neoplasm based on cellularity, architectural arrangement of the follicular cells and presence or absence of colloid.
  • Cytologic diagnoses were correlated with the results of galectin-3 and categorized into 3 groups (benign, indeterminate for malignancy, suspicious for malignancy) and compared with the corresponding histologic diagnoses.
  • RESULTS: When the histologic diagnoses were compared with the cytologic diagnoses, the accuracy in the distinction between benign and malignant cases was 79.5% except for 8 cytologically and 3 histologically indeterminate cases.
  • False positive cases included 8 of 62 (12.9%) nodular hyperplasias and 1 of 42 (2.4%) follicular adenomas.
  • Three follicular tumors of uncertain malignant potential were cytologically categorized as malignant, and all cases showed positivity for galectin-3.
  • CONCLUSION: Galectin-3 could be used as a useful supplementary marker for cytologic diagnosis, although it was not an absolute marker in determining whether a lesion was benign or malignant.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Galectin 3 / metabolism. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514837.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


35. Ponikiewska D, Szcześniak-Kłusek B, Stobiecka E, Jaworska M, Lange D: [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination]. Endokrynol Pol; 2006;57 Suppl A:7-11
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination].
  • In about 10% of cases cytopathologic features do not differentiate unequivocally benign and malignant lesions.
  • In these cases the cytopathologic diagnosis of follicular tumor (FT) or oxyphilic tumor (OT) is most often made.
  • RESULTS: Histopathological diagnosis of neoplasm was made in 48.7% (19/39) FT and 42% (8/19) OT.
  • CONCLUSIONS: These results show how difficult the diagnostics of follicular lesions in FNAB could be because of the frequent overlapping of the cytological features of benign and malignant lesions.
  • Diagnosis of follicular tumor does not mean carcinoma.
  • The use of follicular/ oxyphilic tumor in cytological diagnostic instead of follicular neoplasm seems more advisable.
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091450.001).
  • [ISSN] 2299-8306
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


36. Sillery JC, Reading CC, Charboneau JW, Henrichsen TL, Hay ID, Mandrekar JN: Thyroid follicular carcinoma: sonographic features of 50 cases. AJR Am J Roentgenol; 2010 Jan;194(1):44-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid follicular carcinoma: sonographic features of 50 cases.
  • OBJECTIVE: The purpose of our study was to retrospectively evaluate sonography of thyroid follicular neoplasms for features that would aid in distinguishing follicular carcinoma from follicular adenoma and for any imaging features that distinguish the Hürthle-cell variant of follicular carcinoma from classic follicular carcinoma.
  • MATERIALS AND METHODS: The study cohort consisted of patients with the diagnosis of follicular carcinoma and patients with the diagnosis of follicular adenoma.
  • Fifty patients (25 men and 25 women; median age, 59.5 years) with a diagnosis of follicular carcinoma (27 with classic follicular carcinoma, 22 with Hürthle-cell variant of follicular carcinoma, and one insular variant) in a 6-year period were included.
  • Fifty-two control patients (10 men and 42 women; median age, 46.5 years) were selected from a random sampling of all cases of follicular adenoma during the same time period.
  • All study patients and control patients underwent surgical resection and pathologic analysis of their thyroid follicular neoplasm.
  • RESULTS: Hypoechoic appearance (82% of follicular carcinoma patients vs 50% of follicular adenoma patients; p<0.005; odds ratio [OR]), 0.5; 95% CI, 0.3-0.7), absence of halo (64% of follicular carcinoma patients vs 42% of follicular adenoma patients; p<0.05; OR, 0.4; 95% CI, 0.2-0.9), absence of cystic change (90% of follicular carcinoma patients vs 69% of follicular adenoma patients; p<0.05; OR, 0.2; 95% CI, 0.1-0.7), greater patient age (median age of 59.5 years for follicular carcinoma patients vs 46.5 years for follicular adenoma patients; p<0.05), size of the tumor (median size of 11.75 mL for follicular carcinoma patients vs 5.95 mL for follicular adenoma patients; p<0.05), and male sex (50% of follicular carcinoma patients vs 19.2% of follicular adenoma patients; p<0.005; OR, 3.7; 95% CI, 1.6-8.9) were more frequently associated with follicular thyroid cancer than with benign adenoma.
  • Within the follicular carcinoma subgroup, homogeneous or predominantly homogeneous echotexture (67% of classic follicular carcinoma patients vs 36% of Hürthle-cell variant of follicular carcinoma patients; p<0.05; OR, 3.5; 95% CI, 1.1-11.4) and the presence of calcifications (22% of classic follicular carcinoma patients vs 4% of Hürthle-cell variant of follicular carcinoma patients [multivariate analysis including age]; p < 0.05; OR, 22.9; 95% CI, 2.0-261.9) were associated with classic follicular carcinoma.
  • Greater patient age (median age of 53 years for classic follicular carcinoma patients vs 64.5 years for Hürthle-cell variant of follicular carcinoma patients; p<0.05) was associated with Hürthle-cell variant follicular carcinoma.
  • There was no association between tumor volume, sex, sonographic halo, refractive shadowing, echogenicity, visible invasion, lymph node enlargement, adjacent nonfollicular suspicious lesions, vascularity subtype, and cystic change between the subgroups of follicular carcinoma.
  • CONCLUSION: The sonographic features of follicular adenoma and follicular carcinoma are very similar, but larger lesion size, lack of a sonographic halo, hypoechoic appearance, and absence of cystic change favored a follicular carcinoma diagnosis.
  • Within the follicular carcinoma subgroup, Hürthle-cell variant of follicular carcinoma is more often seen in older patients with nodules having a heterogeneous appearance and lacking internal calcifications.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships.
  • We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


38. Cerutti JM: [Nodule diagnosed as follicular patterned lesion: are biomarkers the promise?]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):832-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nodule diagnosed as follicular patterned lesion: are biomarkers the promise?].
  • [Transliterated title] Nódulos com diagnóstico de padrão folicular: marcadores biológicos são o futuro?
  • A clinical problem is the accurate distinction between benign and malignant forms of follicular lesion.
  • In this review we discuss the thyroid lesions that are common sources of diagnostic error, and grouped together as follicular patterned lesion, and the molecular markers identified by us and others, and that are able to distinguish the benign from the malignant ones.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891248.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DDIT3 protein, human; 0 / Membrane Proteins; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; 147336-12-7 / Transcription Factor CHOP; 94ZLA3W45F / Arginine
  • [Number-of-references] 74
  •  go-up   go-down


39. Hunt J: Understanding the genotype of follicular thyroid tumors. Endocr Pathol; 2005;16(4):311-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding the genotype of follicular thyroid tumors.
  • Tumors of the thyroid with a follicular growth pattern are controversial and can be diagnostically challenging for the pathologist.
  • This group of tumors includes both follicular derived lesions (adenomas and carcinomas) and papillary carcinoma (follicular variant of papillary carcinoma).
  • Other molecular events in tumor suppressor genes may be useful for diagnosis of these tumors as well.
  • None of the mutational markers are very sensitive, and there is some question regarding specificity for malignancy, because mutations have also been described in histologically benign tumors.
  • [MeSH-major] Carcinoma, Papillary, Follicular / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3235-40 [10487693.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Diagn Mol Pathol. 1996 Mar;5(1):45-52 [8919545.001]
  • [Cites] Thyroid. 1998 Jun;8(6):485-9 [9669285.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):185-189 [11493988.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):20-3 [15630436.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1443-50 [9811335.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Hum Pathol. 2003 Apr;34(4):375-80 [12733119.001]
  • [Cites] Diagn Mol Pathol. 2004 Mar;13(1):41-6 [15163008.001]
  • [Cites] J Pathol. 2000 Sep;192(1):32-6 [10951397.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2867-72 [15181070.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):816-21 [15763659.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1549-56 [12414503.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1559-64 [14657716.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Mar;27(3):244-51 [10679913.001]
  • [Cites] Am J Clin Pathol. 2003 Aug;120(2):175-81 [12931546.001]
  • [Cites] Oncogene. 1989 Feb;4(2):159-64 [2648253.001]
  • [Cites] Int J Surg Pathol. 2002 Jan;10(1):15-22 [11927965.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1093-103 [10741739.001]
  • [Cites] Genomics. 2001 Apr 15;73(2):149-60 [11318605.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1053-60 [12651598.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2187-90 [11344225.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1622-6 [11117782.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Nov;5(11):875-85 [15520807.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1237-43 [10646664.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1467-76 [15608688.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 [10566678.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2157-67 [12057919.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 [15001635.001]
  • [Cites] Cancer Lett. 2004 Jun 8;209(1):1-6 [15145515.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):101-6 [14707871.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):732-8 [15238980.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):639-47 [15519853.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3226-35 [12947056.001]
  • [Cites] Genes Chromosomes Cancer. 1997 May;19(1):43-51 [9135994.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):223-9 [2196280.001]
  • [Cites] Cancer Lett. 2003 Jan 28;189(2):117-28 [12490304.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):315-22 [10646883.001]
  • [Cites] FEBS Lett. 2001 Nov 2;507(3):295-8 [11696358.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1615-21 [11117781.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1158-66 [9508203.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 [12697856.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):94-101 [15630448.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):95-100 [9001272.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):354-7 [12519876.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):159-66 [12548161.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • (PMID = 16627918.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 67
  •  go-up   go-down


40. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A: [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms]. Endokrynol Pol; 2006 Jul-Aug;57(4):314-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
  • INTRODUCTION: Estimation of malignancy in thyroid follicular neoplasms is a common diagnostic problem, thus revealing of differences in expression of some antigens in both benign and malignant lesions seems to be essential.
  • The aim of this study is to evaluate the immunohistochemical expression of CD15, galectin-3 and HBME-1 in follicular adenomas and carcinomas.
  • MATERIAL AND METHODS: Samples of 38 follicular adenomas (23 "classical", 5 with intracapsular invasion, 10 oncocytic) and 15 follicular carcinomas (9 "classic", 6 oncocytic) were stained immunohistochemically with anti-CD15, galectin-3 and HBME-1.
  • RESULTS: In the whole group we found statistically significant differences in CD15 expression between follicular adenomas and carcinomas.
  • "Classic" follicular carcinomas (without oncocytic tumors) showed stronger CD15 and HBME- 1 expression than "classic" adenomas.
  • [MeSH-major] Adenoma / chemistry. Antigens, CD15 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / chemistry. Galectin 3 / analysis. Thyroid Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006830.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen
  •  go-up   go-down


42. Schmid KW, Farid NR: How to define follicular thyroid carcinoma? Virchows Arch; 2006 Apr;448(4):385-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to define follicular thyroid carcinoma?
  • The appropriate diagnosis of follicular thyroid carcinoma (FTC) still depends on its histological discrimination from follicular adenoma (including the distinction of benign from malignant oncocytic variants), papillary thyroid carcinoma (particularly from the follicular variants) and poorly differentiated thyroid carcinoma.
  • This review attempts to recapitulate common standards in the diagnosis of FTC, to summarise current molecular data available to distinguish FTC from other benign and malignant tumours and, finally, to outline future perspectives to define FTC on its specific genetic features.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / genetics. Biomarkers, Tumor / genetics. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;385(3):263-70 [7414939.001]
  • [Cites] Ultrastruct Pathol. 1985;8(2-3):131-42 [4060255.001]
  • [Cites] J Pathol. 1998 Nov;186(3):292-9 [10211119.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4155-61 [15806164.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1466-73 [9414190.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):686-94 [8651347.001]
  • [Cites] Mod Pathol. 1989 Mar;2(2):90-3 [2542931.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Ultrastruct Pathol. 1998 Jan-Feb;22(1):91-100 [9491221.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] Pathol Int. 2001 Sep;51(9):680-5 [11696170.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1123-9 [15022277.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):29-35 [15735852.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):950-7 [14983490.001]
  • [Cites] Mod Pathol. 2000 May;13(5):562-9 [10824929.001]
  • [Cites] Cancer. 1977 Jan;39(1):215-22 [832237.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] J Pathol. 1999 Nov;189(3):387-93 [10547601.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] Arch Pathol Lab Med. 1999 Jan;123(1):45-9 [9923836.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):293-6 [15681852.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2864-71 [12782592.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):313-7 [15681855.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Oct;39(4):719-33 [4413723.001]
  • [Cites] Mol Genet Metab. 2002 Mar;75(3):202-8 [11914031.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):246-55 [3706611.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):291-301 [8434709.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):851-5 [6503367.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):37-41 [15735853.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Pathologe. 2003 Sep;24(5):357-72 [12961024.001]
  • [Cites] Curr Top Pathol. 1997;91:37-43 [9018914.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] J Endocrinol Invest. 1998 Jun;21(6):380-5 [9699130.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Hum Pathol. 1984 Mar;15(3):218-28 [6141993.001]
  • [Cites] Diagn Mol Pathol. 1995 Jun;4(2):113-21 [7551291.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):732-8 [15238980.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1512-20 [9850177.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3226-35 [12947056.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1849-55 [6313176.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):90-100 [3843693.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2512-21 [15713710.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):107-12 [3539304.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2005 Sep 05;51(2):177-86 [16171553.001]
  • [Cites] Endocr Pathol. 2002 Winter;13(4):301-11 [12665648.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):47-53 [9013831.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):265-71 [10102611.001]
  • [Cites] Ultrastruct Pathol. 1985;8(4):269-90 [4082297.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):297-305 [15681853.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 May;262(5):368-73 [15368067.001]
  • [Cites] Ultrastruct Pathol. 1998 May-Jun;22(3):271-3 [9793208.001]
  • [Cites] Cancer Lett. 2005 Feb 28;219(1):91-6 [15694668.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):655-68 [6476195.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1195-205 [1748427.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]
  • [Cites] Surgery. 2003 Dec;134(6):1005-12; discussion 1012 [14668734.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1997; author reply 1997-8 [14584085.001]
  • [Cites] Am J Pathol. 1989 Jan;134(1):141-7 [2913822.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):589-95 [15902486.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] Mol Genet Metab. 2001 Feb;72(2):155-63 [11161841.001]
  • [Cites] Surgery. 1996 Dec;120(6):1000-4; discussion 1004-5 [8957486.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1743-8 [9837827.001]
  • (PMID = 16506015.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 93
  •  go-up   go-down


43. Bennett LB, Schnabel JL, Kelchen JM, Taylor KH, Guo J, Arthur GL, Papageorgio CN, Shi H, Caldwell CW: DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. Genes Chromosomes Cancer; 2009 Sep;48(9):828-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma.
  • High-throughput microarray technologies were used to study DNA methylation accompanied by transcriptional changes in follicular lymphoma (FL).
  • Using Methylated CpG Island Amplification with Microarrays to study CpG Island DNA methylation in FL, we discovered widespread hypermethylation of homeobox genes and previously identified targets of polycomb repressive complex 2 (PRC2) in cell lines and primary tumors, but not in benign follicular hyperplasia (BFH).

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2006 Jul;16(7):890-900 [16751344.001]
  • [Cites] Genomics. 2006 May;87(5):572-9 [16487676.001]
  • [Cites] J Pathol. 2006 Dec;210(4):441-9 [17029216.001]
  • [Cites] Leukemia. 2007 Jan;21(1):18-29 [17039231.001]
  • [Cites] Blood. 2007 Jan 15;109(2):747-55 [16954505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Nucleic Acids Res. 2007;35(10):e79 [17517768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13420-5 [17673551.001]
  • [Cites] Genome Res. 2007 Oct;17(10):1529-36 [17785535.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6697-714 [17934479.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] APMIS. 2007 Oct;115(10):1039-59 [18042143.001]
  • [Cites] Int Immunol. 2008 May;20(5):671-81 [18375530.001]
  • [Cites] Pathol Int. 2008 Jun;58(6):334-8 [18477211.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):554-64 [18604447.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1459-65 [18499701.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12979-84 [18753622.001]
  • [Cites] Methods Mol Biol. 2009;507:65-75 [18987807.001]
  • [Cites] Science. 2008 Nov 7;322(5903):945-9 [18818365.001]
  • [Cites] Science. 2008 Nov 7;322(5903):949-53 [18845712.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):282-91 [19118013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):671-8 [19139413.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] Science. 2001 Dec 21;294(5551):2563-6 [11752579.001]
  • [Cites] Mol Cell. 2002 Jan;9(1):133-43 [11804592.001]
  • [Cites] Cell. 2002 Oct 18;111(2):185-96 [12408863.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Biochem Soc Trans. 2004 Dec;32(Pt 6):913-5 [15506922.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):89-93 [3098690.001]
  • [Cites] J Natl Cancer Inst. 1990 Mar 21;82(6):501-9 [2313723.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1586-94 [8123849.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Cell Biol. 2005 Dec;25(24):11047-58 [16314526.001]
  • [Cites] J Pathol. 2006 Mar;208(4):574-89 [16440291.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1281-9 [16247449.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2287-93 [16921485.001]
  • (PMID = 19530241.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA10055; United States / NCI NIH HHS / CA / R03 CA123565; United States / NCI NIH HHS / CA / R33 CA097880; United States / NCI NIH HHS / CA / R03 CA123565-02; United States / NCI NIH HHS / CA / CA100055-04; United States / NCI NIH HHS / CA / CA097880; United States / NCI NIH HHS / CA / R21 CA123018; United States / NCI NIH HHS / CA / CA123565-02; United States / NCI NIH HHS / CA / R21 CA123018-02; United States / NCI NIH HHS / CA / R21 CA097880; United States / NCI NIH HHS / CA / CA123018-02; United States / NCI NIH HHS / CA / R33 CA097880-05; United States / NCI NIH HHS / CA / R01 CA100055; United States / NCI NIH HHS / CA / CA123018; United States / NCI NIH HHS / CA / CA097880-05; United States / NCI NIH HHS / CA / R01 CA100055-04; United States / NCI NIH HHS / CA / CA123565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Carrier Proteins; 0 / HOXA11 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / Polycomb-Group Proteins; 0 / Repressor Proteins; 0 / SUZ12 protein, human; 136601-57-5 / Cyclin D1; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS125568; NLM/ PMC2738630
  •  go-up   go-down


44. Espadinha C, Pinto AE, Leite V: Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin. Oncol Rep; 2009 Oct;22(4):907-13
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underexpression of PPARgamma is associated with aneuploidy and lower differentiation of thyroid tumours of follicular origin.
  • Recently, our group has shown that follicular carcinomas underexpressing PPARgamma protein are more prone to develop distant metastases, to invade locally, to present poorly differentiated areas and to persist after surgery.
  • The aim of the present study was to investigate the association of PPARgamma expression with the degree of differentiation and ploidy status of benign and malignant thyroid neoplasias.
  • DNA cytometric studies, ploidy and S-phase fraction (SPF) determination, and quantitative RT-PCR analysis of molecular markers specific for thyroid follicular cells, namely Tg (thyroglobulin), TSHR (TSH receptor) and NIS (Na+/I- symporter) were compared between thyroid lesions with positive or negative PPARgamma protein expression.
  • This study showed that underexpression of PPARgamma is associated with poor tumour differentiation, aneuploidy and higher cell proliferative activity.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Aneuploidy. PPAR gamma / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Cell Differentiation. Humans. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19724872.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PPAR gamma; 0 / RNA, Messenger
  •  go-up   go-down


45. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW: Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res; 2008 Mar 1;68(5):1572-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and validation of protein abundance differences between follicular thyroid neoplasms.
  • Distinguishing between benign follicular thyroid adenoma (FTA) and malignant follicular thyroid carcinoma (FTC) by cytologic features alone is not possible.
  • These findings provide further insights into the diagnosis, prognosis, and pathophysiology of follicular-derived thyroid neoplasms.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Calreticulin / metabolism. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunohistochemistry / methods. Middle Aged. Models, Biological. Peptides / chemistry. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316623.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calreticulin; 0 / Peptides
  •  go-up   go-down


46. Sakorafas GH, Stafyla V, Kolettis T, Tolumis G, Kassaras G, Peros G: Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease. J Postgrad Med; 2007 Jan-Mar;53(1):23-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic papillary thyroid cancer as an incidental finding in patients treated surgically for presumably benign thyroid disease.
  • AIM: To present our experience with papillary thyroid microcarcinoma of the thyroid as an incidental finding in patients treated surgically for presumably benign thyroid disease.
  • SETTINGS AND DESIGN: Histology reports of patients treated surgically with a preoperative diagnosis of benign thyroid disease were reviewed to identify patients with PTMC.
  • MATERIALS AND METHODS: The files of 380 patients who underwent surgery for presumably benign thyroid disease in our hospital from 1990 to 2002 were reviewed.
  • RESULTS: Twenty-seven patients with PTMC diagnosed incidentally following thyroid surgery for presumably benign thyroid disease (27/380 or 7.1%) (multinodular goiter = 20 patients, follicular adenoma = 6 patients, diffuse hyperplasia of the thyroid = 1 patient) are presented.
  • In 11 patients (40.7%) the tumor was multifocal and in about half of them tumor foci were found in both thyroid lobes.
  • In two patients the tumor infiltrated the thyroid capsule.
  • CONCLUSIONS: PTMC is not an uncommon incidental finding after surgery for presumably benign thyroid disease (7.1% in our series).
  • The possibility of an underlying PTMC should be taken into account in the management of patients with nodular thyroid disease; total/near total thyroidectomy should be considered, at least in selected patients with presumably benign nodular thyroid disease.

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Postgrad Med. 2007 Jan-Mar;53(1):5-6 [17244961.001]
  • [CommentIn] J Postgrad Med. 2007 Jan-Mar;53(1):6-7 [17244962.001]
  • (PMID = 17244966.001).
  • [ISSN] 0022-3859
  • [Journal-full-title] Journal of postgraduate medicine
  • [ISO-abbreviation] J Postgrad Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


47. Gulmann C, Espina V, Petricoin E 3rd, Longo DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL: Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res; 2005 Aug 15;11(16):5847-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma.
  • Follicular lymphoma (FL) is the second most common non-Hodgkin's lymphoma and generally is incurable.
  • To determine whether a proteomic approach could help overcome these obstacles, we procured lymphoid follicles from 20 cases of FL and 15 cases of benign follicular hyperplasia (FH) using laser capture microdissection.
  • [MeSH-major] Apoptosis. Lymphoma, Follicular / pathology. Proteome / analysis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Prognosis. Protein Array Analysis / methods. Proto-Oncogene Proteins c-bcl-2 / analysis. Signal Transduction. Survival Analysis. bcl-2 Homologous Antagonist-Killer Protein / analysis. bcl-2-Associated X Protein / analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115925.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


48. He X, Wei Q, Zhang X, Xiao J, Jin X, Zhu Y, Cui B, Ning G: Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract; 2010 Oct 15;206(10):712-5
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In different tumor entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumor dissemination and poor prognosis.
  • The aim of this study was to examine the immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions.
  • In our study, the CXCR4 expression of the thyroid carcinoma group (including 16 papillary thyroid carcinomas, 18 follicular thyroid carcinomas, 9 poorly differentiated thyroid carcinomas, and 7 medullary thyroid carcinomas) was found to be higher than in the benign lesion group (including 19 cases of Hashimoto's thyroiditis, 15 nodular goiters, and 50 follicular adenomas) (p<0.0001).
  • Within the carcinoma group, the more malignant thyroid carcinoma group (including 9 poorly differentiated thyroid carcinomas and 7 medullary thyroid carcinomas) showed a higher ratio of CXCR4 positivity compared to the less malignant thyroid carcinoma group (including 16 papillary thyroid carcinomas and 18 follicular thyroid carcinomas) (p<0.0001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Receptors, CXCR4 / analysis. Thyroid Diseases / immunology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Carcinoma. Carcinoma, Neuroendocrine. Cell Differentiation. Child. Female. Goiter, Nodular / immunology. Hashimoto Disease / immunology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Thyroid Neoplasms / immunology. Thyroid Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20646838.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; Thyroid cancer, medullary; Thyroid cancer, papillary
  •  go-up   go-down


49. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology diagnosed follicular neoplasm. Endocr J; 2009;56(3):383-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ultrasound features of cytology diagnosed follicular neoplasm.
  • The purpose of this study was to identify clinical and ultrasound (US) features of malignancy in patients using cytological results of follicular neoplasm (FN) in the thyroid.
  • Patient histopathology, age, sex, tumor size, and US characteristics and the color flow pattern of the lesions were analyzed and compared between benign and carcinomas.
  • Twenty five (21.9%) of the 114 FN were found to be follicular carcinomas (FC); 15 minimally invasive FC, 4 widely invasive FC, and 6 FVPTC.
  • Benign included 78 FA, 8 atypical FA, and 3 Hurthle cell adenomas.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164864.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Sato T, Harao M, Nakano S, Jotsuka T, Suda N, Yamashita J: Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Surgery; 2005 May;137(5):552-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma.
  • BACKGROUND: We prospectively tested whether circulating tumor cells could be detected in peripheral blood of patients with thyroid tumors by a reverse transcription-polymerase chain reaction (RT-PCR) to detect carcinoembryonic antigen (CEA) messenger RNA (mRNA).
  • Of 121 preoperative samples from patients with thyroid tumor, 6 were positive (5.0%).
  • Preoperative frequencies of CEA mRNA positivity in benign tumor, papillary carcinoma, follicular variant papillary carcinoma, minimally invasive follicular carcinoma, and widely invasive follicular carcinoma were 0%, 0%, 0%, 44.4% (4/9), and 50.0% (2/4), respectively.
  • Among positive patients only one, who had widely invasive follicular carcinoma, remained positive after surgery.
  • CONCLUSIONS: RT-PCR detection of tumor cells in preoperative blood often can distinguish malignant from benign follicular thyroid tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855928.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
  •  go-up   go-down


51. Terada T: Brain metastasis from thyroid adenomatous nodules or an encapsulated thyroid follicular tumor without capsular and vascular invasion: a case report. Cases J; 2009;2:7180

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis from thyroid adenomatous nodules or an encapsulated thyroid follicular tumor without capsular and vascular invasion: a case report.
  • Because benign-appearing thyroid nodules with metastasis are very rare, the author reports herein four thyroid nodules (one follicular adenoma and three adenomatous nodules) with brain metastasis.
  • Imaging modalities revealed four distinct nodules in the thyroid, and tumorectomies of all nodules were performed under the clinical diagnosis of benign thyroid nodules.
  • Grossly, one of them was a completely encapsulated tumor (35 mm in diameter).
  • Microscopically, the largest tumor was an encapsulated follicular adenoma.
  • The tumor consisted of normofollicles and microfollicles surrounded by a fibrous capsule.
  • Thus, the largest tumor was diagnosed as follicular thyroid adenoma.
  • However, six years later, the patient showed a brain metastasis of thyroid tumor composed of macrofollicles without cellular and nuclear atypia.
  • A diagnosis of metastatic follicular thyroid carcinoma was made.
  • The present case suggests that benign thyroid nodules can metastasize.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2008 Oct;55(5):889-94 [18552462.001]
  • [Cites] J Otolaryngol. 2006 Dec;35(6):366-72 [17380829.001]
  • [Cites] J Mt Sinai Hosp N Y. 1957 Nov-Dec;24(6):804-15 [13481626.001]
  • [Cites] Pathol Int. 1996 Jun;46(6):457-61 [8869998.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):505-24 [11169933.001]
  • [Cites] Chirurg. 1972 Oct;43(10):467-71 [5084873.001]
  • [Cites] Zentralbl Chir. 1972 Sep 9;97(36):1284-9 [5081048.001]
  • [Cites] Acta Chir Ital. 1969 Sep-Oct;25(5):541-56 [5384045.001]
  • [Cites] Endocr Pract. 2004 Jan-Feb;10(1):62-6 [15251624.001]
  • [Cites] Vestn Rentgenol Radiol. 1980 May-Jun;(3):68-70 [7395044.001]
  • (PMID = 19829930.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740070
  •  go-up   go-down


52. Pauzar B, Staklenac B, Loncar B: Fine needle aspiration biopsy of follicular thyroid tumors. Coll Antropol; 2010 Mar;34(1):87-91
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of follicular thyroid tumors.
  • The aim of this research was to make a detailed and objective determination of the morphological characteristics of cells in cytological smears in an attempt to distinguish benign from malignant follicular tumors.
  • The research included 62 patients with cytologically diagnosed follicular or oncocytic tumors, and 15 patients with nodular hyperplasia.
  • We analyzed the cellularity of the smear, cohesion between follicular cells, acinar formations, bare nuclei, characteristics of the nucleus and the cytoplasm, and the presence of colloid.
  • The statistical analysis of cytological parameters has indicated that none of the cytological parameters alone is discriminating enough between non-tumor and tumor changes, or benign and malignant follicular thyroid nodules.
  • The analysis of age, sex, nodule size and ultrasound findings has not shown the correlation between any of these parameters with the malignant or benign follicular tumors.
  • The cytological analysis of the smears for patients with follicular tumors, in combination with clinical data and other diagnostic methods, contributes to more precise diagnostics, but is not sufficient for the differentiation between benign and malignant follicular tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Biopsy, Fine-Needle / standards. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432738.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Croatia
  •  go-up   go-down


53. Clerici T, Kolb W, Beutner U, Bareck E, Dotzenrath C, Kull C, Niederle B, German Association of Endocrine Surgeons: Diagnosis and treatment of small follicular thyroid carcinomas. Br J Surg; 2010 Jun;97(6):839-44
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of small follicular thyroid carcinomas.
  • BACKGROUND: Follicular thyroid microcarcinomas (mFTCs) of 10 mm or less in size rarely manifest clinically and their clinical significance is controversial.
  • Most initial diagnoses had to be revised because of incorrect size assessment or incorrect diagnosis (benign adenoma, papillary thyroid carcinoma (PTC), follicular variant of PTC).
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Austria. Female. Germany. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Switzerland. Thyroidectomy. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473996.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Kaserer K; Perren A; Schmid KW; Köberle-Wührer R; Wenzl E; Asari R; Klinge U; Müller G; Kroell KP; Blankenburg C; Voss H; Cupisti K; Witte J; Knoefel WT; Simon D; Lienenlüke RH; Vorländer C; Wacha H; Schabram J; Lorenz K; Dralle H; Wojciechowski B; Kussmann J; Weber Y; Schürmann G; Goretzki PE; Ulitzer H; Eberle A; Mayer M; Stabenow R; Stegmaier C; Bühlmann R; Schlumpf R; Triponez F; Ess SM
  •  go-up   go-down


54. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L: Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol; 2007 Apr;60(4):377-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.
  • However, the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma expresses more p27 than benign oxyphilic lesions do.
  • The expression of cyclin D3 and p27 was significantly higher in the oxyphilic variant of follicular carcinomas than in non-oxyphilic carcinomas (p<0.001).
  • CONCLUSION: These results show that increased p27 expression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma results from cyclin D3 overexpression.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Cyclins / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cyclin D3. Humans. Immunoprecipitation. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):253-7 [11886339.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1014-9 [11007042.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):587-91 [12890807.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):886-92 [13679452.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7576-86 [14576819.001]
  • [Cites] J Histochem Cytochem. 1982 Nov;30(11):1114-22 [6183312.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] J Pathol. 1998 Jun;185(2):159-66 [9713342.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):735-9 [9720501.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Blood. 1999 Jul 15;94(2):765-72 [10397744.001]
  • [Cites] J Clin Invest. 1999 Oct;104(7):865-74 [10510327.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):242-8 [15671552.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):77-81 [10888749.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3614-20 [10999753.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1038-43 [12379749.001]
  • (PMID = 16798934.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / Cyclins; 0 / Neoplasm Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC2001124
  •  go-up   go-down


55. Misago N, Narisawa Y: Cytokeratin 15 expression in apocrine mixed tumors of the skin and other benign neoplasms with apocrine differentiation. J Dermatol; 2006 Jan;33(1):2-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin 15 expression in apocrine mixed tumors of the skin and other benign neoplasms with apocrine differentiation.
  • To clarify the features of apocrine mixed tumors (AMT) of the skin among benign neoplasms with apocrine differentiation in their relationship to follicular stem cells, we investigated the immunohistochemical expression of CK15 (LHK15 and C8/144B), which is a relatively specific marker of hair follicle stem cells in the bulge, in 35 cases of eight different benign neoplasms with presumed apocrine differentiation.
  • None of the other benign neoplasms with presumed apocrine differentiation showed CK15 expression.
  • In AMT of the skin, the proportion of CK15-positive cells in the follicular or sebaceous differentiation group (78.8%, average of four cases) was significantly higher than the group without this differentiation (8.8%, average of four cases).
  • AMT of the skin are unique among benign neoplasms with apocrine differentiation in their substantial and constant CK15 expression, suggesting that they derive from multipotent epithelial stem cells in the bulge.
  • AMT of the skin with follicular or sebaceous differentiation are considered to show an immature stage of apocrine differentiation still rich in stem cells or to originate from stem cells with an incompletely established apocrine fate.
  • The partially positive reaction for CK15 in syringocystadenomas papilliferum and spiradenoma/cylindroma may depend on the ability to express CK15 in stem cells with an apocrine fate or result from the follicular and apocrine nature of this neoplasm.
  • [MeSH-minor] Adenoma, Sweat Gland / metabolism. Adult. Aged. Biomarkers, Tumor. Case-Control Studies. Cystadenoma / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16469077.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


56. Boutross-Tadross O, Saleh R, Asa SL: Follicular variant papillary thyroid carcinoma arising in struma ovarii. Endocr Pathol; 2007;18(3):182-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular variant papillary thyroid carcinoma arising in struma ovarii.
  • However, the recognition of follicular variant PTC raises the possibility of similar malignancy arising in struma ovarii.
  • We examined 13 cases of struma ovarii to determine if these lesions can exhibit histological, immunohistochemical, and/or molecular features of follicular variant PTC.
  • However, seven of the ten cases with features of follicular variant PTC exhibited a rearranged in transformation (RET)/PTC rearrangement by reverse transcriptase polymerase chain reaction (RT-PCR).
  • The three cases considered to be benign based on histologic and cytologic criteria were negative for CK19 and HBME-1 by immunohistochemistry, and had no evidence of BRAF mutation or ret/PTC-1 and ret/PTC-3 rearrangements.
  • These results indicate that follicular variant PTC can occur in struma ovarii and that such lesions exhibit the same morphologic and immunohistochemical profile as follicular variant PTC in thyroid.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Papillary, Follicular / secondary. Ovarian Neoplasms / secondary. Struma Ovarii. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cohort Studies. DNA Mutational Analysis. Female. Humans. Keratin-19 / metabolism. Middle Aged. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):524-31 [15487449.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):835-9 [15350384.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Int J Gynecol Pathol. 1993 Oct;12(4):333-43 [8253550.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2187-90 [11344225.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1622-6 [11117782.001]
  • [Cites] Pathol Res Pract. 2005;201(5):409-12 [16047952.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):543-8 [12798728.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):224-7 [2910784.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1615-21 [11117781.001]
  • [Cites] Pathology. 2007 Feb;39(1):139-46 [17365830.001]
  • [Cites] Clin Nucl Med. 2006 Jun;31(6):321-4 [16714888.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):116-20 [17478764.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):183-8 [15252732.001]
  • [Cites] Thyroid. 2005 Dec;15(12):1355-61 [16405408.001]
  • (PMID = 18058267.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Keratin-19; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


57. Miyakawa M, Onoda N, Etoh M, Fukuda I, Takano K, Okamoto T, Obara T: Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonography. Endocr J; 2005 Apr;52(2):207-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonography.
  • The aim of this study was to define the preoperative diagnosis of thyroid follicular carcinoma by the vascular pattern and velocimetric parameters using high resolution pulsed and power Doppler ultrasonography (US).
  • We compared the vascular pattern and the velocimetric parameters, such as peak systolic velocity (Vmax), end-diastolic velocity (Vmin), pulsatility index (PI), or resistance index (RI) between follicular adenoma (FA, n = 25) and follicular carcinoma (FC, n = 10) and analysed them by means of receiver characteristics curves (ROC).
  • These color flow imagings by power Doppler US were suggested to be a reliable tool for the differential diagnosis of thyroid follicular tumor with a sensitivity of 87.5% and a specificity of 92%.
  • In conclusion, the evaluation of the vascular pattern and the velocimetric parameters using pulsed and power Doppler ultrasound may provide important information that is useful in making correct differential diagnosis of malignant or benign thyroid follicular tumor preoperatively.
  • [MeSH-major] Adenocarcinoma, Follicular / blood supply. Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / blood supply. Thyroid Neoplasms / ultrasonography. Ultrasonography, Doppler, Pulsed

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863949.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Michailidi C, Giaginis C, Stolakis V, Alexandrou P, Klijanienko J, Delladetsima I, Chatzizacharias N, Tsourouflis G, Theocharis S: Evaluation of FAK and Src expression in human benign and malignant thyroid lesions. Pathol Oncol Res; 2010 Dec;16(4):497-507
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.
  • Focal Adhesion Kinase (FAK) and Src have been reported to regulate tumor growth, invasion, metastasis and angiogenesis.
  • The present study aimed to evaluate by immunohistochemistry the clinical significance of FAK and Src expression in 108 patients with benign and malignant thyroid lesions.
  • Total FAK expression provided a distinct discrimination between malignant and benign (p = 0.00001), as well as between papillary carcinoma and hyperplastic nodules thyroid lesions (p = 0.00005), being also associated with follicular cells' proliferative capacity (p = 0.0003).
  • In malignant thyroid lesions, total FAK expression was associated with tumor size (p = 0.0455), and presence of capsular (p = 0.0102) and lymphatic (p = 0.0173) invasion.
  • Total Src expression was borderline increased in cases of papillary carcinoma compared to hyperplastic nodules (p = 0.0993), being also correlated with tumor size (p = 0.0169).
  • FAK and Src expression was ascribed to a significant extent to the phosphorylated forms of the enzymes, which provided a better discrimination between malignant and benign thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2006;71(5-6):417-22 [17687194.001]
  • [Cites] Prog Biophys Mol Biol. 1999;71(3-4):435-78 [10354709.001]
  • [Cites] Pathol Oncol Res. 2009 Dec;15(4):645-50 [19381877.001]
  • [Cites] Pathol Oncol Res. 2008 Dec;14(4):457-60 [18415710.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19031-4 [1382065.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):53-60 [7678609.001]
  • [Cites] Ann Surg Oncol. 1996 Jan;3(1):100-5 [8770310.001]
  • [Cites] Toxicology. 2008 Mar 12;245(1-2):1-10 [18215454.001]
  • [Cites] J Biol Chem. 1997 Nov 28;272(48):30455-62 [9374537.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1087-95 [15466376.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):710-5 [15483349.001]
  • [Cites] J Cell Sci. 1996 Jul;109 ( Pt 7):1787-94 [8832401.001]
  • [Cites] Pediatr Endocrinol Rev. 2007 Jun;4(4):317-28 [17643079.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Jul;29(7):929-34 [9375372.001]
  • [Cites] Histol Histopathol. 2008 May;23 (5):629-50 [18283648.001]
  • [Cites] Biochimie. 2007 May;89(5):613-24 [17397984.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):261-7 [12462387.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Jan;12(1):51-64 [12517254.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 23:4221-30 [11069767.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):413-21 [8054685.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 13;243(2):503-8 [9480838.001]
  • [Cites] Surgery. 2003 Aug;134(2):221-6 [12947321.001]
  • [Cites] J Pathol. 1996 Dec;180(4):383-8 [9014858.001]
  • [Cites] Pathol Oncol Res. 2009 Jun;15(2):173-81 [18987997.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):359-74 [12884911.001]
  • [Cites] Mini Rev Med Chem. 2008 Sep;8(10):1053-63 [18782057.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5028-33 [12941830.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12 ):2724-32 [16998832.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1315-28 [17907961.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):35-52 [16823799.001]
  • [Cites] Nature. 1995 Oct 12;377(6549):539-44 [7566154.001]
  • [Cites] Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi [17673125.001]
  • [Cites] Eur J Endocrinol. 2008 Nov;159(5):493-505 [18728120.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33714-21 [9837958.001]
  • [Cites] Dig Dis Sci. 2008 Jun;53(6):1728-34 [17932753.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1379-86 [18487549.001]
  • [Cites] Oncogene. 2002 Apr 11;21(16):2513-24 [11971186.001]
  • [Cites] Front Biosci. 1999 Jan 15;4:D102-13 [9889179.001]
  • [Cites] World J Surg. 2006 Feb;30(2):219-26 [16425085.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2307-18 [15073106.001]
  • [Cites] J Cell Biol. 1992 Nov;119(4):905-12 [1385445.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Nov;7(6):681-4 [18045062.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):104-11 [15246215.001]
  • [Cites] J Hepatol. 2001 Jul;35(1):68-73 [11495044.001]
  • [Cites] APMIS. 2010 Mar;118(3):210-21 [20132187.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):140-5 [12838315.001]
  • [Cites] Lung Cancer. 2006 Sep;53(3):263-71 [16842883.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1289-94 [15861214.001]
  • (PMID = 20405349.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.2 / Focal Adhesion Kinase 1; EC 2.7.10.2 / PTK2 protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src)
  •  go-up   go-down


59. Zhao J, Leonard C, Gemsenjäger E, Heitz PU, Moch H, Odermatt B: Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. Oncol Rep; 2008 Feb;19(2):329-37
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling.
  • It is difficult to distinguish benign from malignant follicular thyroid tumors by histological or cytological examination.
  • The goal of this study was to reveal gene expression variations between benign and malignant follicular lesions of the thyroid gland.
  • We investigated gene expression profiles from 24 follicular thyroid tumors (12 carcinomas and 12 adenomas) and 13 normal thyroid tissues using high-density human cDNA arrays.
  • The identification of gene expression changes was based on signal intensity ratios of tumor versus normal thyroid parenchyma.
  • Expression patterns of a set of known genes were found to be significantly different between follicular adenomas and follicular carcinomas.
  • Our results demonstrate a potential use of gene expression profiling for differentiating benign from malignant follicular thyroid tumors.
  • A detailed investigation of the differentially expressed genes could give new insights into molecular pathways of malignant transformation of thyroid follicular neoplasm and may help to develop a molecular tool for the preoperative differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Gene Expression Profiling. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202778.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


60. Finley DJ, Lubitz CC, Wei C, Zhu B, Fahey TJ 3rd: Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid; 2005 Jun;15(6):562-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling.
  • BACKGROUND: Thyroid nodules are common and most are benign.
  • Previous data from our laboratory and others has suggested that gene profiling can accurately distinguish between benign and malignant thyroid nodules and provide new leads in the study of thyroid tumorigenesis.
  • Current preoperative techniques do not permit distinction between neoplastic and hyperplastic follicular neoplasms.
  • These studies were undertaken to determine whether benign follicular tumors could be subcategorized by molecular profiling.
  • METHODS: Molecular profiles of 8 follicular adenomas and 8 hyperplastic nodules were analyzed by oligonucleotide microarray analysis.
  • Seven additional benign follicular lesions were then added to the analysis.
  • A hierarchical clustering analysis was performed on all 23 samples, utilizing the gene list generated from the test set, to examine the groups for potential differences and the ability of the gene list to distinguish tumor types.
  • The analysis was able to identify follicular adenomas with a sensitivity of 84.6% and a specificity of 100%.
  • CONCLUSIONS: These data indicate that benign thyroid lesions can be separated into distinct groups through molecular profiling.
  • Expression profiling may ultimately allow us to distinguish potentially malignant from benign follicular nodules.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029122.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


61. Migliario M, Rimondini L, Valente G: Benign fibrous histiocytoma of the lower lip. J Craniofac Surg; 2010 Nov;21(6):2024-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign fibrous histiocytoma of the lower lip.
  • Benign fibrous histiocytoma (BFH) is one of the most common tumors of the superficial and deep soft tissues; it is commonly localized on the skin of the extremities and presents as a slow growing solitary nodule, made up of a mixture of fibroblastic and histiocytic cells.
  • This rare tumor should be considered in the differential diagnosis of the oral soft-tissue neoplasms.
  • [MeSH-major] Histiocytoma, Benign Fibrous / diagnosis. Lip Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Diagnosis, Differential. Female. Giant Cells / pathology. Hemosiderin / analysis. Histiocytes / pathology. Humans. Lymphocytes / pathology. Middle Aged. Neoplasms, Second Primary / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119493.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9011-92-1 / Hemosiderin
  •  go-up   go-down


62. Garcia EA, Simões K, Wakamatsu A, Ressio RA, Alves VA, Longatto-Filho A, Camargo RS: Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions. Endocr Pathol; 2010 Jun;21(2):101-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions.
  • In order to evaluate the value of LVD in benign and malignant thyroid lesions, we analyzed 110 thyroidectomy specimens using D2-40, a specific marker for lymphatic vessels and vascular endothelial growth factor C (VEGF-C), the most potent molecule of lymphatic proliferation.
  • LVD was significantly different between papillary and follicular carcinomas in total (p = 0.045) and peritumoral area (p = 0.042).
  • Follicular adenoma and follicular carcinoma showed an important difference of intra- (p = 0.019) and peritumoral (p = 0.033) LVD.
  • VEGF-C was more markedly expressed in malignancies than in benign lesions (p = 0.0001).
  • Almost all cancers with high positive VEGF-C expression also exhibited increased peritumoral LVD (p = 0.049) when compared with the benign lesions.
  • Indeed, the high peritumoral LVD of malignant thyroid lesions is an important finding for surgery planning and supports the practice of total thyroidectomy in malignant thyroid neoplasm's since the lymphatic peritumoral vessels definitely are an escape path for tumor cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphatic Vessels / pathology. Thyroid Neoplasms / pathology. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Antibodies, Monoclonal. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):730-8 [17103065.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):931-44 [16954441.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8364-71 [16322297.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):45-51 [17604828.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):426-30 [12888807.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):777-94 [16364190.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8413-20 [15623620.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1315-20 [11888898.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):171-80 [12539171.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7144-9 [15534085.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1424-31 [15920537.001]
  • [Cites] Histopathology. 2009 Nov;55(5):514-24 [19912357.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):640-5 [1463115.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1611-25 [17117184.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):292-306 [16557281.001]
  • [Cites] Physiol Rev. 2002 Jul;82(3):673-700 [12087132.001]
  • [Cites] Mol Divers. 2006 Nov;10(4):515-27 [16972015.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):133-8 [18087718.001]
  • [Cites] Pharmacol Ther. 2009 Jul;123(1):117-41 [19374919.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Jun;27(3):157-61 [16121637.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • (PMID = 20336393.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor C; 0 / monoclonal antibody D2-40
  •  go-up   go-down


63. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A: HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol; 2010 Oct 25;118(5):287-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
  • BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine-needle aspiration (FNA) (eg, "suspicious for follicular neoplasm") prove to be benign at the time of surgical resection.
  • Ancillary tests in current use are limited in their ability to improve the preoperative detection of malignant follicular thyroid nodules.
  • Studies using paraffin-embedded tissue have indicated that high mobility group AT-hook 2 (HMGA2) overexpression is present in a high percentage of malignant thyroid neoplasms but not in benign thyroid neoplasms.
  • In the current study, the ability of HMGA2 overexpression analysis to preoperatively distinguish benign from malignant thyroid nodules by reverse transcriptase-polymerase chain reaction (RT-PCR) on suspicious cytologic smears was evaluated.
  • With an HMGA2 overexpression change of 5.9-fold or greater compared with a thyroid tumor cell line as a positive cutoff, the test was found to have the following overall performance for detecting malignant nodules: sensitivity of 71%, specificity of 97%, positive predictive value of 94%, and negative predictive value of 84%.
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Cytodiagnosis / methods. Diagnosis, Differential. Female. Goiter / diagnosis. Goiter / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20597139.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / RNA, Messenger
  •  go-up   go-down


64. Foukakis T, Gusnanto A, Au AY, Höög A, Lui WO, Larsson C, Wallin G, Zedenius J: A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer; 2007 Jun;14(2):381-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A PCR-based expression signature of malignancy in follicular thyroid tumors.
  • The diagnosis of follicular thyroid carcinoma (FTC) in the absence of metastasis can only be established postoperatively.
  • In this study, we aimed to identify transcriptional markers of malignancy and high-risk disease in follicular thyroid tumors.
  • The expression levels of 26 potential markers of malignancy were determined in a panel of 75 follicular thyroid tumors by a TaqMan quantitative RT-PCR approach.
  • The metastatic potential could be predicted in all four cases with apparently benign or minimally invasive (MI) disease at the time of diagnosis, but poor long-term outcome.
  • In addition, a second model was produced by implementing two genes (TERT and TFF3), which was able to distinguish adenomas from de facto carcinomas.
  • When this model was tested in an independent series of atypical adenomas (AFTA) and MI-FTCs, 16 out of 17 AFTAs were classified as 'benign', while MI-FTCs with vascular invasion (sometimes referred to as 'moderately invasive') and/or large tumor size tended to classify in the 'malignant' group.
  • The reported models can be the foundation for the development of reliable preoperative diagnostic and prognostic tests that can guide the therapeutic approach of follicular thyroid neoplasms with indeterminate cytology.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Gene Expression. Genes, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639052.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


65. Łukieńczuk T, Kaliszewski K, Zołedziewska M, Jonkisz A, Dmochowska G, Dobrut M, Rogoliński J, Dobosz T: [SNP polymorphism of LGALS3BP gene in patients with benign and malignant thyroid tumours]. Endokrynol Pol; 2006;57 Suppl A:45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [SNP polymorphism of LGALS3BP gene in patients with benign and malignant thyroid tumours].
  • INTRODUCTION: The aim of the study was estimation of occurrence of SNP (single nucleotide polymorphism) sites in LGALS3BP gene in patients with benign and malignant thyroid tumors and analysis of correlation between their frequency and the histological type of thyroid lesions.
  • MATERIAL AND METHODS: The studied group consisted of 58 patients, 24 with papillary thyroid carcinomas, 19 with nodular goiters and 15 with follicular adenomas.
  • CONCLUSION: Single nucleotide polymorphism (SNP) of LGALS3BP gene (found in NCBI) database are not characteristic for papillary thyroid cancer, follicular adenomas and nodular goiter.
  • [MeSH-major] Adenoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Carrier Proteins / genetics. Glycoproteins / genetics. Goiter, Nodular / genetics. Polymorphism, Single Nucleotide. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091456.001).
  • [ISSN] 2299-8306
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / LGALS3BP protein, human
  •  go-up   go-down


66. Riesco-Eizaguirre G, Santisteban P: New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr Relat Cancer; 2007 Dec;14(4):957-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
  • Whereas the prevalence of nodular thyroid disease worldwide is high, malignant conversion from benign thyroid nodules is rare.
  • The most common type of thyroid cancer--papillary thyroid carcinoma--stands out among solid tumours because many of the tumour-initiating events have been identified.
  • All of them function in a single pathway--the RTK/RAS/RAF/MAPK pathway--and obey an 'exclusivity principle': one and only one component of the pathway is mutated in a single tumour.
  • This highlights the requirement of this signal transduction pathway for the transformation to thyroid cancer and paves the way to targeted therapies against a tumour with a mutation in a known gene or any gene upstream of the target.
  • In this review, we attempt to summarise the most recent advances in thyroid follicular cell-derived cancers research and their potential clinical impact that may change the management of thyroid cancer in the near future.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / genetics. Thyroid Neoplasms / therapy
  • [MeSH-minor] Humans. Multigene Family. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-ret / genetics. Treatment Outcome. Tumor Suppressor Protein p53 / genetics


67. Gulcelik NE, Gulcelik MA, Kuru B: Risk of malignancy in patients with follicular neoplasm: predictive value of clinical and ultrasonographic features. Arch Otolaryngol Head Neck Surg; 2008 Dec;134(12):1312-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignancy in patients with follicular neoplasm: predictive value of clinical and ultrasonographic features.
  • OBJECTIVE: To identify clinical and ultrasonographic features that may help in predicting malignant tumors in patients with a diagnosis of follicular neoplasm on findings from fine-needle aspiration cytology (FNAC) because FNAC diagnosis of follicular neoplasm does not differentiate a benign tumor from a malignant tumor.
  • DESIGN: Prospective study of 98 patients having a diagnosis of follicular neoplasm on FNAC.
  • PATIENTS: Ninety-eight patients with thyroid nodules diagnosed by FNAC as being a follicular neoplasm.
  • Older age, male sex, solitary nodule, and larger nodule size were not predictive for malignant neoplasms in patients with follicular neoplasm cytologic findings.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075128.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Koh YW, Kim JW, Lee SW, Choi EC: Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions. Surg Endosc; 2009 Sep;23(9):2053-60
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions.
  • A second 1.0-cm skin incision was made along the upper margin of the mammary areola on the tumor side for insertion of a 12-mm trocar.
  • RESULTS: Postoperative pathology showed 11 follicular adenomas, 1 follicular carcinoma, and 40 benign thyroid lesions.
  • CONCLUSION: Although the aspect of invasiveness could be improved, endoscopic hemithyroidectomy via a unilateral axillo-breast approach without gas insufflation is safe and effective and appears to provide better cosmetic results and a shorter operation time than other endoscopic methods for managing selective unilateral benign thyroid lesions.
  • [MeSH-minor] Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Axilla. Breast. Drainage. Feasibility Studies. Female. Hematoma / etiology. Humans. Length of Stay. Male. Middle Aged. Postoperative Complications / etiology. Seroma / etiology. Vocal Cord Paralysis / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2008 Jan;22(1):154-7 [17440778.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):226-31 [16921301.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12):2166-71 [17479328.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12 ):1741-5 [12140635.001]
  • [Cites] Am J Surg. 2002 Mar;183(3):286-9 [11943128.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):82-5 [11044518.001]
  • [Cites] Surgery. 1997 Nov;122(5):893-901 [9369889.001]
  • [Cites] Anesth Analg. 1997 May;84(5):1154-6 [9141952.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] World J Surg. 2007 Mar;31(3):601-6 [17308853.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201 [12819505.001]
  • [Cites] Surg Endosc. 1997 Aug;11(8):877 [9266657.001]
  • [Cites] Arch Surg. 2002 Mar;137(3):301-4; discussion 305 [11888453.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2007 Feb;17(1):21-5 [17362173.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5 [12598753.001]
  • [Cites] J Surg Oncol. 1994 Dec;57(4):235-8 [7990478.001]
  • [Cites] World J Surg. 2007 Dec;31(12):2302-6; discussion 2307-8 [17566819.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):268-72 [11525373.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4 [10872517.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):697-703 [10359365.001]
  • (PMID = 18528625.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Duchi S, Fagnocchi L, Cavaliere V, Hsouna A, Gargiulo G, Hsu T: Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability. Development; 2010 May;137(9):1493-503
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drosophila VHL tumor-suppressor gene regulates epithelial morphogenesis by promoting microtubule and aPKC stability.
  • Mutations in the human von Hippel-Lindau (VHL) genes are the cause of VHL disease, which displays multiple benign and malignant tumors.
  • Using an established follicular epithelial model in Drosophila, we show that the Drosophila VHL gene is involved in epithelial morphogenesis via stabilizing microtubule bundles and aPKC.
  • Importantly, paclitaxel-induced stabilization of microtubules can rescue the aPKC localization phenotype in Drosophila VHL mutant follicle cells.
  • The results establish a developmental function of the VHL gene that is relevant to its tumor-suppressor activity.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1993 Apr;117(4):1223-37 [8404527.001]
  • [Cites] Development. 2008 Feb;135(3):463-71 [18094021.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):352-60 [7958405.001]
  • [Cites] Cell. 1995 Jul 14;82(1):67-76 [7606787.001]
  • [Cites] Development. 1997 Oct;124(19):3871-80 [9367443.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):959-68 [9651579.001]
  • [Cites] Exp Cell Res. 2004 Dec 10;301(2):139-46 [15530850.001]
  • [Cites] Oncogene. 2004 Nov 11;23(53):8688-94 [15467749.001]
  • [Cites] Curr Biol. 2005 Feb 8;15(3):276-82 [15694314.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Mar;6(3):233-47 [15738988.001]
  • [Cites] Biochem J. 2006 Jan 15;393(Pt 2):471-80 [16176182.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1553-60 [16452212.001]
  • [Cites] J Cell Sci. 2006 Mar 15;119(Pt 6):979-87 [16525119.001]
  • [Cites] J Biol Chem. 2006 Apr 28;281(17):12069-80 [16505488.001]
  • [Cites] J Am Soc Nephrol. 2006 Jul;17(7):1801-6 [16775032.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6903-7 [16849532.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2054-6 [16969113.001]
  • [Cites] J Cell Sci. 2006 Oct 15;119(Pt 20):4155-63 [17038542.001]
  • [Cites] J Cell Biol. 2006 Nov 20;175(4):547-54 [17101696.001]
  • [Cites] Dev Cell. 2007 May;12(5):727-38 [17488624.001]
  • [Cites] FEBS Lett. 2007 Oct 2;581(24):4571-6 [17825299.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):15-27 [17936701.001]
  • [Cites] Nat Protoc. 2007;2(10):2467-73 [17947988.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):685-90 [18006292.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):361-9 [18297059.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4649-57 [18559510.001]
  • [Cites] Nat Cell Biol. 2008 Oct;10(10):1208-16 [18806787.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(3):1089-101 [19073886.001]
  • [Cites] Dev Biol. 2009 May 15;329(2):294-305 [19285057.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):994-1001 [19620968.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):544-7 [10591216.001]
  • [Cites] Oncogene. 2000 Jun 1;19(24):2803-11 [10851083.001]
  • [Cites] Science. 2000 Jun 16;288(5473):2013-8 [10856208.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):355-61 [11006129.001]
  • [Cites] J Cell Biol. 2000 Nov 13;151(4):891-904 [11076972.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2929-36 [12019174.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1568-81 [12080094.001]
  • [Cites] Bioessays. 2002 Aug;24(8):690-5 [12210528.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1955-9 [12471248.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):46-52 [12510193.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):53-8 [12510194.001]
  • [Cites] Nat Cell Biol. 2003 Jan;5(1):64-70 [12510195.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):766-74 [12700771.001]
  • [Cites] Curr Biol. 2003 Apr 29;13(9):734-43 [12725730.001]
  • [Cites] Traffic. 2004 Jan;5(1):1-9 [14675420.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):845-54 [15177032.001]
  • [Cites] J Cell Biol. 2004 Aug 16;166(4):549-57 [15302858.001]
  • [Cites] Cell. 1990 Jun 1;61(5):787-99 [2344615.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):73-8 [17912253.001]
  • [Cites] J Cell Sci. 1993 Aug;105 ( Pt 4):993-1000 [8227220.001]
  • (PMID = 20388653.001).
  • [ISSN] 1477-9129
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA078582-100005; United States / NCI NIH HHS / CA / R01CA109860; United States / NCI NIH HHS / CA / R01 CA109860; United States / NCI NIH HHS / CA / P01 CA078582-100005; United States / NCI NIH HHS / CA / P01 CA078582; United States / NIGMS NIH HHS / GM / GM057843-08; United States / NIGMS NIH HHS / GM / R01 GM057843; United States / NIGMS NIH HHS / GM / R01 GM057843-08; United States / NCI NIH HHS / CA / R01 CA109860-06; United States / NCI NIH HHS / CA / P01CA78582; United States / NCI NIH HHS / CA / CA109860-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drosophila Proteins; EC 2.7.11.13 / Protein Kinase C-alpha; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC2853850
  •  go-up   go-down


70. Ko CJ, Shintaku P, Binder SW: Comparison of benign keratoses using p53, bcl-1, and bcl-2. J Cutan Pathol; 2005 May;32(5):356-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of benign keratoses using p53, bcl-1, and bcl-2.
  • While cell-cycle markers have been used to differentiate benign vs. malignant lesions and to classify malignant lesions, benign keratoses have not been well studied using such markers.
  • We hypothesized that inflammation or irritation of benign keratoses may be related to a shift in the cell cycle.
  • We compared the immunohistochemical staining patterns of 10 seborrheic keratoses (SKs), 10 inflamed seborrheic keratoses (iSKs), and 10 inverted follicular keratoses (IFKs) using antibodies to p53, bcl-1, and bcl-2.
  • [MeSH-major] Cyclin D1 / metabolism. Keratosis / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15811121.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  •  go-up   go-down


71. Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, Gasparri G: The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest; 2010 Jun;33(6):378-81
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions.
  • Aim of the study was to consider the diagnostic accuracy of galectine-3 (GAL3) in the pre-operative cytological evaluation of follicular lesions.
  • Based on preoperative cytological reports, 40 patients had pre-operative malignant results, and 60 patients (46 females and 14 males) showed follicular lesions.
  • The GAL3 expression in neoplastic and benign lesions was significantly different (GAL3+ in 16 out of 29 neoplastic lesions, GAL3+ 0 out of 31 benign lesions, p<0.01).
  • Even comparing the GAL3 positivity between the follicular adenomas (0 GAL3+ out of 20) and the group of follicular carcinomas (5 GAL3+ out of 6), we found a statistically significant difference (p<0.01).
  • CONCLUSIONS: Based on the data from our experience, the patients with a cytological diagnosis of GAL3 positive follicular neoformation should be referred for surgery without any further immunocytological testing.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Galectin 3 / analysis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Diagnostic Errors. Female. Gene Expression. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Predictive Value of Tests. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Thyroid Gland / chemistry. Thyroid Gland / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):950; author reply 950-1 [12574240.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):663-710 [8608777.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):579-83 [12708901.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):255-7 [11740046.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):687-91 [9167684.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Am J Med. 1994 Aug;97(2):152-7 [8059781.001]
  • (PMID = 19625759.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


72. Gonçalves AJ, Carvalho LH, Serdeira K, Nakai MY, Malavasi TR: Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells. Sao Paulo Med J; 2007 Sep 6;125(5):289-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the prevalence of the glutathione S-transferase (GST) system in malignant and benign thyroid tumor cells.
  • The aim of this study was to compare the frequencies of these genes in patients with benign and malignant tumors of the thyroid gland.
  • DESIGN AND SETTINGS: This was a cross-sectional clinical trial carried out in the Head and Neck Surgery Division, Faculdade de Medicina da Santa Casa de São Paulo.
  • METHODS: Samples of thyroid tissue were collected from 32 patients and divided into two groups: benign tumor (A) and malignant tumor (B).
  • CONCLUSION: In this study, there was no relationship between the presence of the GSTT1 and GSTM1 genes and the benign and malignant thyroid tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma, Papillary / genetics. Glutathione Transferase / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Cross-Sectional Studies. Female. Genotype. Humans. Male

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094897.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


73. Torregrossa L, Faviana P, Filice ME, Materazzi G, Miccoli P, Vitti P, Fontanini G, Melillo RM, Santoro M, Basolo F: CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid; 2010 May;20(5):495-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
  • BACKGROUND: The cytological discrimination between benign and malignant follicular-patterned lesions of the thyroid can represent a diagnostic challenge, even for experienced pathologists.
  • METHODS: Expression of CXCR4, HBME-1, and gal-3 was examined immunohistochemically in total of 100 aspirates of thyroid lesions, categorized as benign (n = 22), indeterminate lesion (n = 43), suspicious of papillary thyroid carcinoma (n = 10), or malignant (n = 25) by preoperative cytology.
  • CONCLUSIONS: An immunohistochemical panel, including CXCR4, could be useful in the differential diagnosis between benign and malignant well-differentiated follicular-patterned thyroid lesions.
  • [MeSH-major] Biomarkers, Tumor / chemistry. Carcinoma, Papillary, Follicular / chemistry. Galectin 3 / chemistry. Receptors, CXCR4 / chemistry. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450430.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Receptors, CXCR4
  •  go-up   go-down


74. Oliveira-Neto HH, Spíndula-Filho JV, Dallara MC, Silva CM, Mendonça EF, Batista AC: Unicystic ameloblastoma in a child: a differential diagnosis from the dentigerous cyst and the inflammatory follicular cyst. J Dent Child (Chic); 2007 Sep-Dec;74(3):245-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unicystic ameloblastoma in a child: a differential diagnosis from the dentigerous cyst and the inflammatory follicular cyst.
  • Unicystic ameloblastoma (UA) is a benign epithelial odontogenic tumor of the jaws with an aggressive potential that commonly occurs in children.
  • This cystic odontogenic neoplasm is generally asymptomatic and found during routine radiographs.
  • The purposes of this report were to describe a case of UA involving the crown of the unerupted right mandibular second premolar in an 11-year-old girl under orthodontic treatment, and discuss its diagnosis and radiographic and microscopic findings, emphasizing its distinction from the dentigerous cyst and the inflammatory follicular cyst.
  • [MeSH-minor] Bicuspid / physiopathology. Child. Dentigerous Cyst / diagnosis. Diagnosis, Differential. Female. Follicular Cyst / diagnosis. Humans. Tooth, Unerupted / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482524.001).
  • [ISSN] 1935-5068
  • [Journal-full-title] Journal of dentistry for children (Chicago, Ill.)
  • [ISO-abbreviation] J Dent Child (Chic)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Giovanella L, Ceriani L, Ghelfo A, Maffioli M: Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers; 2008 Jan-Mar;23(1):54-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland.
  • The present study was planned to assess the serum expression of Cyfra 21.1 in patients with benign thyroid nodules and thyroid malignancies.
  • We enrolled 135 patients with histologically proven benign thyroid nodules (n=79) and thyroid carcinomas (n=56).
  • No differences were found in serum Cyfra 21.1 levels between patients with benign nodules and patients with carcinomas.
  • When thyroid malignancies were subdivided according to tumor histology, serum Cyfra 21.1 increased significantly from classical differentiated thyroid carcinomas (papillary or follicular) to less differentiated or undifferentiated carcinomas (poorly differentiated or anaplastic).
  • [MeSH-major] Antigens, Neoplasm / blood. Keratin-19 / blood. Keratins / blood. Thyroid Neoplasms / blood. Thyroid Nodule / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Apoptosis. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Peptide Fragments / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409152.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


76. Naresh KN: Nodal marginal zone B-cell lymphoma with prominent follicular colonization - difficulties in diagnosis: a study of 15 cases. Histopathology; 2008 Feb;52(3):331-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal marginal zone B-cell lymphoma with prominent follicular colonization - difficulties in diagnosis: a study of 15 cases.
  • AIMS: While colonization of reactive follicles is well described in mucosa-associated lymphoid tissue lymphoma, this is not fully appreciated in nodal marginal zone B-cell lymphoma (NMZL).
  • METHODS AND RESULTS: Fifteen NMZLs with prominent follicular colonization are described, 14 of which were referrals from other hospitals.
  • All cases had a follicular pattern and showed prominent 'follicular colonization'.
  • In many follicles the colonization was partial, and follicles also had a reactive germinal centre component.
  • The phenomenon of follicular colonization was highlighted by immunohistochemistry.
  • The benign follicle centre cells expressed CD20, CD10 and Bcl-6 and were negative for Bcl-2 and MUM1.
  • Partially colonized follicles showed a 'moth-eaten' appearance on CD10, Bcl-2, Bcl-6 and MUM1 immunohistochemistry.
  • CONCLUSION: Recognizing and appreciating follicular colonization in a subset of NMZLs, appropriate use of immunohistochemistry and knowledge of immunohistological features can aid in making the correct diagnosis.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269584.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA: Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma. Int J Surg Pathol; 2005 Jan;13(1):37-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Hürthle cell adenoma with papillary architecture: a benign lesion mimicking oncocytic papillary carcinoma.
  • The diameter of the tumor cell nuclei ranged from 5.6 to 7.2 microns.
  • Many nodules had nuclei displaying a fine chromatin pattern somewhat resembling those of PTC, but these were present in <20% of the tumor cells.
  • In view of (1) the encapsulation and the uniformity of the constituent cells, (2) the negative or weak immunoreactivity for galectin-3 and HBME and negative to moderate immunoreactivity for CK19, and (3) the absence or paucity of nuclear criteria for the diagnosis of PTC and the absence of lymph node metastasis in all study cases, we believe that these lesions represent the papillary variant of oncocytic follicular adenoma (Hürthle cell adenoma).
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary, Follicular / diagnosis. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Chromatin / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735853.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin
  •  go-up   go-down


78. Arora N, Scognamiglio T, Zhu B, Fahey TJ 3rd: Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg; 2008 Jul;32(7):1237-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do benign thyroid nodules have malignant potential? An evidence-based review.
  • BACKGROUND: Benign thyroid tumors account for most nodular thyroid disease.
  • Determination of whether a thyroid nodule is benign or malignant is a major clinical dilemma and underlies the decision to proceed to surgery in many patients.
  • Although the accuracy of thyroid nodule fine-needle aspiration (FNA) has reduced the need for surgery over the years, questions regarding how to follow FNA-designated benign nodules remain unresolved.
  • This is true at least in part because of uncertainty over whether some benign nodules harbor malignant potential.
  • RESULTS: Review of our recent 10-year experience indicates that 2% of thyroid malignancies arise within a preexisting benign thyroid nodule.
  • In addition, both cytologic and molecular tumor markers, including Gal-3, CITED1, HBME-1, Ras, RET/PTC, and PAX8/PPAR gamma, have been identified in some histopathologically classified benign nodules.
  • Gene expression profiling suggests that follicular adenomas and Hürthle cell adenomas have similarities to both benign and malignant tumors, suggesting that some of these tumors are premalignant.
  • In addition, 10% of surgically excised follicular tumors are encapsulated follicular lesions with nuclear atypia, which have been termed "well-differentiated tumors of uncertain malignant potential."
  • CONCLUSION: Some benign thyroid nodules have malignant potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2008 Dec;32(12):2744-6 [18787892.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1255-64 [16900519.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):16-8 [11791591.001]
  • [Cites] Endocr Pathol. 2002 Fall;13(3):207-11 [12446919.001]
  • [Cites] Diagn Mol Pathol. 1996 Mar;5(1):45-52 [8919545.001]
  • [Cites] J Clin Invest. 1992 May;89(5):1517-22 [1569189.001]
  • [Cites] Thyroid. 2005 Jun;15(6):562-8 [16029122.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1016-23 [12170088.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):185-189 [11493988.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1096-104 [15292926.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):893-910 [9735140.001]
  • [Cites] Ann Ital Chir. 2005 May-Jun;76(3):219-24 [16355851.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1336-40 [15371949.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2312-8 [8635037.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):38-46 [17520704.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Jul;49(3):376-80 [17001889.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):625-30 [8503736.001]
  • [Cites] Thyroid. 2004 Aug;14(8):616-21 [15320975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1667-72 [1717926.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):495-8; discussion 499 [7725734.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1631-7 [16998461.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):411-26 [8521787.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52 [12161538.001]
  • [Cites] Ann Intern Med. 2003 Feb 18;138(4):315-8 [12585829.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):287-94 [9516913.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2745-52 [12788883.001]
  • [Cites] Head Neck Surg. 1981 Jan-Feb;3(3):216-30 [7007286.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Surgery. 2004 Dec;136(6):1160-8 [15657571.001]
  • [Cites] Oncogene. 1989 Feb;4(2):159-64 [2648253.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Apr;50(4):529-35 [10468914.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6 [11443191.001]
  • [Cites] AMA Arch Pathol. 1954 Dec;58(6):554-63 [13217570.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2733-9 [10946873.001]
  • [Cites] Jpn J Clin Oncol. 1988 Dec;18(4):297-302 [3204680.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Postgrad Med. 1981 Jul;70(1):107-9, 112, 116 [7243694.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):878-82 [10690905.001]
  • [Cites] J Postgrad Med. 2007 Jul-Sep;53(3):157-60 [17699987.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3631-5 [9768676.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):832-6 [1890154.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] ANZ J Surg. 2007 Jun;77(6):450-4 [17501885.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] Pathol Int. 1995 Jan;45(1):45-50 [7704243.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1 [17717450.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2157-67 [12057919.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] Endocr Pathol. 2006 Fall;17(3):235-41 [17308360.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1512-20 [9850177.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6 [716909.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3226-35 [12947056.001]
  • [Cites] Eur J Surg Oncol. 2001 Nov;27(7):631-5 [11669590.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1993-7 [15274390.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):275-9 [11740048.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] Surgery. 2005 Dec;138(6):1042-8; discussion 1048-9 [16360389.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3323-6 [12926070.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):223-31 [15972966.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):354-7 [12519876.001]
  • [Cites] J Korean Med Sci. 2007 Aug;22(4):621-8 [17728499.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):797-807 [6660352.001]
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):186-93 [12162676.001]
  • [Cites] Mol Endocrinol. 1990 Oct;4(10):1474-9 [2283998.001]
  • [Cites] Histopathology. 2001 Jul;39(1):25-32 [11454041.001]
  • [Cites] Arch Intern Med. 1990 Jul;150(7):1422-7 [2196027.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2414-23 [16595592.001]
  • [Cites] Am J Clin Pathol. 1988 Jul;90(1):72-6 [3389346.001]
  • (PMID = 18327528.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


79. Proietti A, Giannini R, Ugolini C, Miccoli M, Fontanini G, Di Coscio G, Romani R, Berti P, Miccoli P, Basolo F: BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid; 2010 Nov;20(11):1263-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
  • BACKGROUND: The cytological discrimination between benign and malignant follicular-patterned lesions of the thyroid can represent a diagnostic challenge, even for experienced pathologists.
  • To attempt to clarify this diagnostic problem, we analyzed the BRAF status of thyroid tumors in a group of patients with follicular variant of papillary thyroid carcinoma (FVPTC) and its correlation with cytomorphological features.
  • Each case had a previous fine-needle aspiration diagnosis classified according to the British Thyroid Association Guidelines categorized as inadequate (Thy1) (n = 19), benign (Thy2) (n = 19), follicular lesion and follicular lesion with atypia (Thy3) (n = 109), suspicious of PTC (Thy4) (n = 29), or malignant (Thy5) (n = 11).
  • RESULTS: The BRAF status of each tumor was correlated with the cytological classes.
  • 54.5% and 27.6% of Thy5 and Thy4, respectively, were BRAF-mutated, against 12.1% of follicular lesions and 9.3% of follicular lesion with atypia (Thy3).
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Papillary / pathology. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Thyroid Gland / pathology. Thyroid Nodule / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20950194.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


80. Mitmaker E, Alvarado C, Bégin LR, Trifiro M: Microsatellite instability in benign and malignant thyroid neoplasms. J Surg Res; 2008 Nov;150(1):40-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability in benign and malignant thyroid neoplasms.
  • The purpose of this study was to further define the distribution of MSI in both normal and neoplastic thyroid follicular epithelium.
  • DESIGN: Using laser capture microdissection, cells from both normal and tumor tissue were individually collected.
  • RESULTS: Forty benign and malignant thyroid tumors were compared with their adjacent normal thyroid follicular tissue and were analyzed for MSI.
  • Nine of 14 papillary thyroid carcinomas and 10/16 of follicular thyroid carcinomas demonstrated MSI at > or =30-40% of loci tested.
  • For benign follicular adenomas, 9/10 demonstrated microsatellite stability or low-frequency MSI.
  • In addition our study showed a significant difference in MSI frequency between follicular adenomas and follicular carcinomas.
  • More importantly, the technique of laser capture microdissection allows for more accurate selection of benign, malignant, and normal DNA.
  • [MeSH-major] Carcinoma, Papillary / pathology. DNA Mismatch Repair. DNA, Neoplasm / chemistry. Microsatellite Instability. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243241.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


81. Niepomniszcze H, Suárez H, Pitoia F, Pignatta A, Danilowicz K, Manavela M, Elsner B, Bruno OD: Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes. Thyroid; 2006 May;16(5):497-503
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma presenting as autonomous functioning thyroid nodule and containing an activating mutation of the TSH receptor (T620I) and a mutation of the Ki-RAS (G12C) genes.
  • Most autonomous functioning thyroid nodules (AFTN) are benign thyroid follicular neoplasms.
  • We report a case of follicular carcinoma presenting as an AFTN causing subclinical hyperthyroidism in a 64-year-old woman who had a 6-cm hot nodule in the left thyroid lobe.
  • Genomic DNA was extracted from paraffin-embedded tissues from the tumor and extratumoral thyroid tissue.
  • We hypothesize that the combination of these two mutations might have played an important role in both the hyperfunction of the tumor and the carcinogenetic process.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Gene Expression Regulation, Neoplastic. Genes, ras / genetics. Mutation. Receptors, Thyrotropin / genetics. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756473.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Receptors, Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


82. Bongiovanni M, Gremaud M, Moulin CS, Scheidegger C, Biton C, Clément S: Macrofollicular variant of follicular thyroid carcinoma: a clinical, cytologic, morphologic, and image analysis study of a unique case. Ann Diagn Pathol; 2009 Apr;13(2):101-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrofollicular variant of follicular thyroid carcinoma: a clinical, cytologic, morphologic, and image analysis study of a unique case.
  • Thyroid lesions composed of large follicles that contain abundant colloid are usually regarded as benign hyperplastic or adenomatous nodules both by fine-needle aspiration cytology and histology.
  • In such cases, the pathologist is less likely to request a complete inclusion of the capsule into paraffin block and to look for vascular and/or capsular invasion, the only criteria that permit the differential diagnosis between a benign nodule and a follicular carcinoma.
  • We report the first case of a follicular thyroid carcinoma composed predominantly (>90%) of macrofollicles with a surface area that was up to 5 times larger than the surface area of normal follicles, as calculated with an image analysis system.
  • The tumor was classified as a minimally invasive follicular carcinoma, macrofollicular variant.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302958.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kolomecki K, Maciaszczyk P, Stepien H, Stepien T, Kuzdak K, Ulanska J: P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors. Bratisl Lek Listy; 2005;106(10):297-300
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors.
  • The aim of the study was to evaluate p53 and sFasL plasma concentration in patients with benign and malignant thyroid tumors.
  • The study population was composed of 33 patients with thyroid carcinoma and 10 patients with follicular carcinoma (tumor types were verified by fine-needle biopsy).
  • The results revealed high p53 and sFasL plasma concentration in patients with benign and malignant thyroid tumors.
  • [MeSH-major] Apoptosis. Carcinoma / physiopathology. Membrane Glycoproteins / blood. Thyroid Neoplasms / physiopathology. Tumor Necrosis Factors / blood. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Fas Ligand Protein. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541608.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


84. Kojima M, Miyawaki S, Takada S, Kashiwabara K, Igarashi T, Nakamura S: Lymphoplasmacytic infiltrate of regional lymph nodes in Kuttner's tumor (chronic sclerosing sialadenitis): a report of 3 cases. Int J Surg Pathol; 2008 Jul;16(3):263-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoplasmacytic infiltrate of regional lymph nodes in Kuttner's tumor (chronic sclerosing sialadenitis): a report of 3 cases.
  • Regional lymph nodes of Küttner's tumor from 3 patients showed reactive follicular hyperplasia and prominent interfollicular plasmacytosis.
  • The present 3 cases indicated that regional lymph node of Küttner's tumor may show reactive follicular hyperplasia and prominent interfollicular plasmacytosis and should be differentiated from various benign and malignant lymphoproliferative disorders including systemic rheumatic disease, plasma cell type of Castleman disease, and lymph node involvement of marginal B-cell lymphoma of the mucosa-associated lymphoid tissue type showing prominent plasma cell differentiation.

  • Genetic Alliance. consumer health - Sialadenitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18573783.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin G
  •  go-up   go-down


85. Jung YH, Kang MS: Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of thyroid gland: a case report. J Korean Med Sci; 2010 Nov;25(11):1683-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite follicular variant of papillary carcinoma and mucoepidermoid carcinoma of thyroid gland: a case report.
  • Pathologically, the tumor had two distinct tumor components with intermingled areas: follicular variant of papillary carcinoma and mucoepidermoid carcinoma.
  • Several small cysts lined by benign ciliated columnar epithelia suggesting that this tumor had originated from solid cell nest were seen around the tumor.
  • Tumor cells of papillary carcinoma are positive for TTF-1, thyroglobulin but negative for CEA, calcitonin and p63.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jul;13(7):802-7 [10912941.001]
  • [Cites] Am Surg. 2001 Oct;67(10):979-83 [11603557.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):43-8 [12527712.001]
  • [Cites] Dis Esophagus. 2003;16(3):265-7 [14641323.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Cancer. 1977 Jan;39(1):210-4 [832236.001]
  • [Cites] Histopathology. 1984 Sep;8(5):847-60 [6083973.001]
  • [Cites] J Pathol. 1988 Jul;155(3):191-200 [3045277.001]
  • [Cites] Arch Pathol Lab Med. 1990 Oct;114(10):1049-52 [2222147.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1209-15 [7573680.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1099-108 [7557943.001]
  • [Cites] Surg Today. 1995;25(9):843-7 [8555707.001]
  • [Cites] Eur J Surg Oncol. 1995 Dec;21(6):692 [8631425.001]
  • [Cites] Pathol Res Pract. 1995 Dec;191(12):1214-21 [8927569.001]
  • [Cites] Am Surg. 1998 Apr;64(4):307-11 [9544139.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):291-3 [9641234.001]
  • [Cites] Am J Otolaryngol. 2005 Mar-Apr;26(2):138-41 [15742270.001]
  • [Cites] Pathol Int. 2008 Nov;58(11):741-4 [18844942.001]
  • [Cites] Lung Cancer. 2009 Jan;63(1):159-60 [18992960.001]
  • [Cites] Hum Pathol. 2009 Jul;40(7):1029-35 [19269016.001]
  • (PMID = 21060764.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins; 9007-12-9 / Calcitonin; 9010-34-8 / Thyroglobulin
  • [Other-IDs] NLM/ PMC2967012
  • [Keywords] NOTNLM ; Carcinoma, Mucoepidermoid / Carcinoma, Papillary / Solid Cell Nests / Thyroid Gland
  •  go-up   go-down


86. Shimizu K, Nakamura K, Kobatake S, Satomura S, Maruyama M, Tajiri J, Kato R: Discrimination of thyroglobulin from thyroid carcinoma tissue and that from benign thyroid tissues with use of competitive assay between lectin and anti-thyroglobulin antibody. Rinsho Byori; 2007 May;55(5):428-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination of thyroglobulin from thyroid carcinoma tissue and that from benign thyroid tissues with use of competitive assay between lectin and anti-thyroglobulin antibody.
  • Thyroglobulin is produced only by thyroid follicular cells, and has a molecular weight of 660,000 and carbohydrate content of approximately 10%.
  • The ratio of Lens culinaris agglutinin-reactive thyroglobulin to thyroglobulin was significantly lower in thyroid carcinoma than in normal thyroid tissue, Graves' disease and benign thyroid tumor.
  • However, no differences between malignant and benign tissues were observed with the other lectins tested.
  • Differences in carbohydrate chain on thyroglobulin were observed between malignant and benign thyroid tissues.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593687.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantibodies; 0 / Lectins; 0 / anti-thyroglobulin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


87. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol; 2006 May;34(5):330-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
  • The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate.
  • The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change.
  • Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial.
  • Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).
  • The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V: Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int; 2005 Nov;55(11):694-702
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
  • Proliferation and apoptosis-related transcription factor immunoexpression patterns were concomitantly investigated in tissue sections of normal thyroid, goiters, follicular adenomas and well-differentiated papillary and follicular carcinomas using antibodies against prothymosin alpha, E2F-1, p53, Bcl2, and Bax proteins.
  • [MeSH-minor] Adenoma / pathology. Adenoma / physiopathology. Adolescent. Adult. Aged. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / physiopathology. DNA-Binding Proteins / analysis. DNA-Binding Proteins / immunology. DNA-Binding Proteins / physiology. E2F1 Transcription Factor / analysis. E2F1 Transcription Factor / immunology. E2F1 Transcription Factor / physiology. Female. Goiter / pathology. Goiter / physiopathology. Humans. Immunohistochemistry. Male. Middle Aged. Protein Precursors / analysis. Protein Precursors / immunology. Protein Precursors / physiology. Repressor Proteins / analysis. Repressor Proteins / immunology. Repressor Proteins / physiology. Thymosin / analogs & derivatives. Thymosin / analysis. Thymosin / immunology. Thymosin / physiology. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / immunology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / immunology. Tumor Suppressor Proteins / physiology. bcl-2-Associated X Protein / analysis. bcl-2-Associated X Protein / immunology. bcl-2-Associated X Protein / physiology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271081.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BCLAF1 protein, human; 0 / DNA-Binding Proteins; 0 / E2F1 Transcription Factor; 0 / Protein Precursors; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


89. Giaginis C, Zarros A, Alexandrou P, Klijanienko J, Delladetsima I, Theocharis S: Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS; 2010 Mar;118(3):210-21
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions.
  • Coxsackievirus and adenovirus receptor (CAR) expression on tumor cells is associated with sensitivity to adenoviral infection, being considered as a surrogate marker for monitoring and/or predicting adenovirus-mediated gene therapy.
  • The aim of this study was to evaluate the clinical significance of CAR expression in human benign and malignant thyroid lesions.
  • CAR protein expression was assessed immunohistochemically on paraffin-embedded thyroid tissues from 107 patients with benign and malignant lesions and was statistically analyzed in relation to histopathologic type; tumor size; lymph node metastasis; capsular, lymphatic and vessel invasion; as well as follicular cells' proliferative capacity.
  • CAR immunoreactivity was significantly increased in malignant compared with that in benign thyroid lesions (p = 0.00002).
  • Both malignant and benign thyroid lesions with enhanced follicular cells' proliferative capacity showed significantly increased CAR immunoreactivity (p = 0.00027).
  • In malignant thyroid lesions, enhanced CAR immunoreactivity was significantly associated with larger tumor size (p = 0.0067).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132187.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CLMP protein, human; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / Receptors, Virus
  •  go-up   go-down


90. Hedayati M, Kołomecki K, Pasieka Z, Korzeniowska M, Kuzdak K: [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors]. Endokrynol Pol; 2005 May-Jun;56(3):252-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
  • The aim of this study is to evaluate the concentrations of crucial angiogenic cytokine VEGF and its soluble receptors in peripheral blood of patients with benign and malignant thyroid tumors.
  • The study comprised 35 patients with thyroid cancer and 10 patients with follicular neoplasm, both diagnosed by means of ultrasound-guided fine-needle aspiration biopsy.
  • Analysing obtained results, we demonstrated high VEGF concentrations and low soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors.
  • Disequilibrium of the above-mentioned angiogenic factor concentrations is probably essential for the growth and progression of benign and malignant thyroid tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Receptors, Vascular Endothelial Growth Factor / blood. Thyroid Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adult. Aged. Biopsy. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350718.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


91. Brzeziańska E, Cyniak-Magierska A, Sporny S, Pastuszak-Lewandoska D, Lewiński A: Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions. Neuro Endocrinol Lett; 2007 Aug;28(4):341-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
  • 1) an assessment of CCND1 gene expression level in benign and malignant thyroid lesions and 2) the evaluation of possible correlations between gene expression and the histopathological variants of papillary thyroid carcinoma (PTC), or tumour size, classified according to TNM definition of primary tumours (in case of PTC only) or patient's sex or age.
  • DESIGN: Thirty five (35) tissue samples were analysed: 24 cases of PTC, 4 cases of medullary thyroid carcinoma (MTC), 4 cases of follicular adenoma (FA) and 3 cases of nodular goitre (NG).
  • On the other hand, the correlation was observed between RQ values and tumour size.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Biopsy. Cyclin D. Female. Gene Expression Regulation, Neoplastic. Goiter, Nodular / diagnosis. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693985.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin D; 0 / Cyclins
  •  go-up   go-down


92. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT: Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J; 2005 Apr;52(2):281-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
  • We report the case of a 52-year-old man with the history of two previous thyroid operations for benign goiters, who developed a recurrent goiter.
  • In the pathohistological examination the specimen showed a 5 cm follicular carcinoma and a 0.3 cm papillary microcarcinoma in the right lobe as well as a 1.5 cm medullary carcinoma in the left lobe.
  • There is no known common cause of these three different tumor types and they developed most independently from each other.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863962.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Nosé V, Volante M, Papotti M: Hyalinizing trabecular tumor of the thyroid: an update. Endocr Pathol; 2008;19(1):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumor of the thyroid: an update.
  • Hyalinizing trabecular tumor (HTT) is a rare thyroid tumor of follicular cell origin with a trabecular pattern of growth and marked intratrabecular hyalinization.
  • This tumor is known to share morphological and architectural similarities with paraganglioma and medullary thyroid carcinoma, as well as the nuclear features and RET/PTC1 translocations of papillary thyroid carcinoma.
  • Of great interest is the characteristic strong peripheral cytoplasmic and membranous staining of the tumor cells with MIB1 immunostain, not seen in any other thyroid neoplasm.
  • Although cases of malignant HTT have been recorded, HTT should be considered a benign neoplasm or, at most, a neoplasm of extremely low malignant potential.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Calcitonin / analysis. Cell Nucleus / pathology. Chromogranin A / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Paraganglioma / pathology. Sex Characteristics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2002 Mar;40(3):291-3 [11895496.001]
  • [Cites] Adv Anat Pathol. 2002 Jan;9(1):7-11 [11756755.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1366-72 [9416692.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):364-9 [11788677.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1683-4 [11117792.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):506-10 [15487446.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jun;127(6):715-7 [12741896.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1057-61 [10574603.001]
  • [Cites] Acta Med Austriaca. 1996;23(1-2):65-8 [8767518.001]
  • [Cites] J Pathol. 1999 Nov;189(3):387-93 [10547601.001]
  • [Cites] Ann Diagn Pathol. 1999 Dec;3(6):331-40 [10594284.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):494-8 [12657934.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1065-75 [15980887.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):192-7 [8119720.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):816-21 [15763659.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):220-3 [17525638.001]
  • [Cites] Int J Surg Pathol. 2002 Jan;10(1):15-22 [11927965.001]
  • [Cites] Histopathology. 1996 Apr;28(4):357-62 [8732345.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):575-8 [10757406.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1622-6 [11117782.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):118-25 [9888712.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):883-8 [9167720.001]
  • [Cites] Histopathology. 1989 Sep;15(3):211-24 [2478437.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):399-404 [12789921.001]
  • [Cites] Ultrastruct Pathol. 1998 Jan-Feb;22(1):39-46 [9491214.001]
  • [Cites] Histopathology. 1997 Dec;31(6):525-33 [9447383.001]
  • [Cites] Pathology. 1994 Oct;26(4):429-31 [7892044.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1615-21 [11117781.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):877-81 [10843292.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):495-6 [15487444.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):115-9 [2916458.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):748-53 [9236830.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):359-62 [2343693.001]
  • [Cites] Am J Surg Pathol. 1987 Aug;11(8):583-91 [2441614.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):792-6 [14756146.001]
  • [Cites] J Pathol. 2004 Feb;202(2):247-51 [14743508.001]
  • [Cites] Histopathology. 1997 Oct;31(4):330-5 [9363448.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):859-67 [15223954.001]
  • (PMID = 17960500.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Ki-67 Antigen; 68238-35-7 / Keratins; 9007-12-9 / Calcitonin
  •  go-up   go-down


94. Bouraoui S, Khaddar KR, Ben Tekaya N, Kchir N, Mekni A, Ben Osman DA, Zitouna MM, Haouet S: [Warty dyskeratoma or "follicular dykeratoma": a clinicopathologic features of a new entity]. Tunis Med; 2005 Apr;83(4):227-9
MedlinePlus Health Information. consumer health - Warts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Warty dyskeratoma or "follicular dykeratoma": a clinicopathologic features of a new entity].
  • INTRODUCTION: Warty dyskeratoma is a rare, benign, epithelial tumor characterized by a variable clinicopathologic spectrum.
  • DISCUSSION: Warty dyskeratoma is an epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966669.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


95. Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol; 2005 Jun;123(6):826-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-Cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry.
  • The diagnosis of B-cell chronic lymphoproliferative disorders is a great challenge when made in a background of polyclonal B cells.
  • We studied the diagnostic usefulness of aberrant CD22 expression for differentiating neoplastic from benign B cells by 4-color flow cytometry.
  • Of 56 cases of B-cell chronic lymphoproliferative disorders, we found that neoplastic cells showed aberrant CD22 expression in 39 (70%) of 56 cases, including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, hairy cell leukemia, and follicular lymphoma.
  • Aberrant CD22 expression is a useful marker for detection of monoclonal B cells admixed with numerous benign polyclonal B cells.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Differentiation, B-Lymphocyte / biosynthesis. B-Lymphocytes / cytology. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / biosynthesis. Lectins / biosynthesis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, B-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899772.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulin Light Chains; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


96. Yüksel M, Eziddin S, Wardelmann E, Biersack HJ: 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Rev Esp Med Nucl; 2006 Sep;25(5):316-9
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
  • A patient with suspicion of a neuroendocrine tumor of the pancreas underwent a somatostatin receptor scintigraphy using 111In-Pentetreotide.
  • Normal thyroid tissue and thyroid disorders, such as cancers, Hashimoto's thyroiditis, and adenomas often show increased uptake of 111In-pentetreotide resulting in a possible false positive interpretation in patients with neuroendocrine tumor.
  • Adding a 48h planar image might contribute to the differential diagnosis between benign or malignant lesions, as in the present case where the uptake decreased in an adenoma after 48 hours.
  • [MeSH-minor] Chromogranin A / analysis. Diagnosis, Differential. False Positive Reactions. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Pancreatic Neoplasms / radionuclide imaging. Receptors, Somatostatin / metabolism. Serotonin / analysis. Thyroglobulin / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173778.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Indium Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 333DO1RDJY / Serotonin; 51110-01-1 / Somatostatin; 9010-34-8 / Thyroglobulin; G083B71P98 / pentetreotide
  •  go-up   go-down


97. Pavelić K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S, Kusić Z, Spaventi S, Bura M: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. Mutat Res; 2006 Jul 25;599(1-2):45-57
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
  • Several oncogenes and tumor-suppressor genes are involved either as early or late event in thyroid gland carcinogenesis.
  • Status of these genes as well as intensity of apoptosis was analyzed in tumor tissues by molecular genetic methods, immunohistochemistry, and FACS-scan analysis.
  • We found higher incidence of p53 mutation and aberrant processing of FHIT mRNA in malignant tumors (papillary, follicular, medullary and anaplastic carcinomas) and in those tumors with distant metastasis.
  • The growth of p53(-)/FHIT(-) follicular carcinoma of human origin was much faster in nude mice than p53(+)/FHIT(+) follicular carcinoma, and mice had shorter survival rate.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Genes, p53. Mutation. Neoplasm Proteins / genetics. Thyroid Diseases / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Apoptosis. Female. Flow Cytometry. Gene Expression. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Mice. Mice, Nude. Middle Aged. Molecular Biology. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698048.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


98. Collet JF, Hurbain I, Prengel C, Utzmann O, Scetbon F, Bernaudin JF, Fajac A: Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. Br J Cancer; 2005 Nov 14;93(10):1175-81
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples.
  • Fine-needle aspiration cytology, which is well established to be accurate for the diagnosis of thyroid cancer, may be inconclusive for the follicular thyroid neoplasms.
  • After establishing an easy processing of aspirates for galectin-3 immunodetection, a series of aspirates categorised as benign (n=63), malignant (n=17) or undeterminate (n=34) was prospectively analysed for galectin-3.
  • The majority of lesions (94%) classified as benign by cytology or after surgery was negative for galectin-3.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Galectin 3 / analysis. Galectin 3 / immunology. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Cell Line, Tumor. Humans. Immunohistochemistry. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 1999 Dec 1;75(3):505-14 [10536372.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):87-95 [15742329.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4635-40 [11156213.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5152-8 [11701669.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):275-9 [11740048.001]
  • [Cites] Histopathology. 2002 Jan;40(1):80-7 [11903601.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Biochim Biophys Acta. 2002 Sep 19;1572(2-3):285-93 [12223276.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Glycoconj J. 2004;19(7-9):543-9 [14758078.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6363-7 [15374939.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7527-36 [15326483.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Arch Intern Med. 1989 Sep;149(9):2007-9 [2774778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3466-70 [7682704.001]
  • [Cites] J Biol Chem. 1994 Feb 11;269(6):4424-30 [8308013.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2206-12 [8156527.001]
  • [Cites] Cytopathology. 2005 Jun;16(3):132-8 [15924608.001]
  • [Cites] Ann Intern Med. 2005 Jun 7;142(11):926-31 [15941700.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):442-9 [8618236.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5272-6 [9393748.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • [Cites] Thyroid. 1998 Jul;8(7):565-9 [9709908.001]
  • [Cites] Exp Cell Res. 1998 Dec 15;245(2):294-302 [9851870.001]
  • [Cites] Head Neck. 2004 Nov;26(11):960-6 [15386597.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):361-7 [10956411.001]
  • (PMID = 16251880.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  • [Other-IDs] NLM/ PMC2361502
  •  go-up   go-down


99. Aron M, Kapila K, Verma K: Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. Indian J Pathol Microbiol; 2006 Jul;49(3):376-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
  • This study was conducted to study the role of galectin-3 in differentiating benign from malignant thyroid nodules onfine needle aspirates (FNAC).
  • The cytology diagnosis of these cases was: papillary carcinoma (25), follicular neoplasm (16), adenomatous goiter (20), hyperplastic nodule (5), medullary carcinoma (5) and anaplastic carcinoma (1).
  • Galectin-3 positivity was seen in 80% of papillary carcinomas, 37.5% offollicular neoplasms and in 60% of benign nodules.
  • However, since it is also expressed in a variety of benign lesions, its role as a pre-surgical markerfor differentiating benignfrom malignant thyroid nodules is limited.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Galectin 3 / metabolism. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001889.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


100. Sorrentino F, Atzeni J, Romano G, Buscemi G, Romano M: [Differentiated microcarcinoma of the thyroid gland]. G Chir; 2010 Jun-Jul;31(6-7):277-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The thyroid microcarcinoma is a tumor with maximum diameter of 10 mm (WHO).
  • The papillary microcarcinoma is the most common form of thyroid cancer, followed by follicular microcarcinoma.
  • The aim of our study is to assess the frequency of microcarcinoma, the association of benign thyroid disease himself and the controversial surgery.
  • RESULTS: 42 carcinomas were detected, of which 24 PTMC and 1 follicular microcarcinoma.
  • The PTMC was associated with cancer in only 2 cases (papillary carcinoma and parathyroid carcinoma) in the remaining thyroid tissue was suffering from benign disease (20 goiters, 3 Hashimoto thyroiditis, a trabecular adenoma).
  • Microcarcinoma and benign thyroid disease association (76.92% of cases) was high.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / surgery. Lymph Node Excision. Thyroid Neoplasms / surgery. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646369.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement